Precision targeted therapy of ovarian cancer

The review is aimed at describing modern approaches to detection as well as precision and personalized treatment of ovarian cancer. Modern methods and future directions of nanotechnology-based targeted and personalized therapy are discussed. [Display omitted]

Saved in:
Bibliographic Details
Published inJournal of controlled release Vol. 243; pp. 250 - 268
Main Authors Sapiezynski, Justin, Taratula, Oleh, Rodriguez-Rodriguez, Lorna, Minko, Tamara
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 10.12.2016
Subjects
animal ovaries
Animals
Female
Genetic profiling
Humans
Molecular Targeted Therapy
Nanotechnology
Nanotechnology - methods
ovarian neoplasms
Ovarian Neoplasms - diagnosis
Ovarian Neoplasms - therapy
Personalized medicine
Precision Medicine - methods
siRNA
Targeted therapy
therapeutics
PARE
CDC
Targeted therapy
MIBI
PLD
PARP
MDA
SRM
LHRH
SNP
EMA
DOC
SNS
cDNA
PFS
ADCC
Genetic profiling
TDS
FRα
OS
P4
VEGF
qRT-PCR
mRNA-seq
siRNA
Personalized medicine
ER
MAB
QOL
WGA
PEG
HER
CEL-seq
NGS
Nanotechnology
Online AccessGet full text
ISSN0168-3659
1873-4995
1873-4995
DOI10.1016/j.jconrel.2016.10.014

Cover

Abstract The review is aimed at describing modern approaches to detection as well as precision and personalized treatment of ovarian cancer. Modern methods and future directions of nanotechnology-based targeted and personalized therapy are discussed. [Display omitted]
AbstractList The review is aimed at describing modern approaches to detection as well as precision and personalized treatment of ovarian cancer. Modern methods and future directions of nanotechnology-based targeted and personalized therapy are discussed.
The review is aimed at describing modern approaches to detection as well as precision and personalized treatment of ovarian cancer. Modern methods and future directions of nanotechnology-based targeted and personalized therapy are discussed. [Display omitted]
The review is aimed at describing modern approaches to detection as well as precision and personalized treatment of ovarian cancer. Modern methods and future directions of nanotechnology-based targeted and personalized therapy are discussed.The review is aimed at describing modern approaches to detection as well as precision and personalized treatment of ovarian cancer. Modern methods and future directions of nanotechnology-based targeted and personalized therapy are discussed.
Author Taratula, Oleh
Sapiezynski, Justin
Rodriguez-Rodriguez, Lorna
Minko, Tamara
AuthorAffiliation 3 Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903
2 Department of Pharmaceutical Sciences, Oregon State University, Portland, OR 97239
1 Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, Piscataway, NJ 08854
4 Department of Obstetrics and Gynecology, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ 08901
AuthorAffiliation_xml – name: 2 Department of Pharmaceutical Sciences, Oregon State University, Portland, OR 97239
– name: 3 Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903
– name: 1 Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, Piscataway, NJ 08854
– name: 4 Department of Obstetrics and Gynecology, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ 08901
Author_xml – sequence: 1
  givenname: Justin
  surname: Sapiezynski
  fullname: Sapiezynski, Justin
  organization: Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, United States
– sequence: 2
  givenname: Oleh
  surname: Taratula
  fullname: Taratula, Oleh
  organization: Department of Pharmaceutical Sciences, Oregon State University, Portland, OR 97239, United States
– sequence: 3
  givenname: Lorna
  surname: Rodriguez-Rodriguez
  fullname: Rodriguez-Rodriguez, Lorna
  organization: Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, United States
– sequence: 4
  givenname: Tamara
  surname: Minko
  fullname: Minko, Tamara
  email: minko@rci.rutgers.edu
  organization: Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, United States
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27746277$$D View this record in MEDLINE/PubMed
BookMark eNqFkU1vEzEQhi1URNPATwDtkQMb_P0hJCpU8SVVggOcLa93tnW0sYPtROq_x1FCBVxysT0z7zsaz3OFLmKKgNBLglcEE_l2vVr7FDPMK9rCllthwp-gBdGK9dwYcYEWraB7JoW5RFelrDHGgnH1DF1SpbhsxwK9-Z7BhxJS7KrLd1Bh7Oo9ZLd96NLUpb3LwcXOu-ghP0dPJzcXeHG6l-jnp48_br70t98-f735cNt7oXDtuceCGuCK64EoLD3QSU9UaT0wMRhsjHK0PUFQybmnwuCBSyMHYZwcpWNL9P7Yd7sbNjB6iDW72W5z2Lj8YJML9t9KDPf2Lu2tIIaYtoAlen1qkNOvHZRqN6F4mGcXIe2KpW0VlGmm9Vkp0UxwppiUTfrq77Ee5_mzzSYQR4HPqZQM06OEYHugZtf2RM0eqB3SjVrzvfvP50N1tUFpvwvzWff10Q0NyT5AtsUHaLzG0NhWO6ZwpsNv-Lq1MQ
CitedBy_id crossref_primary_10_3390_cancers14225711
crossref_primary_10_1124_jpet_118_254979
crossref_primary_10_1016_j_procbio_2023_02_011
crossref_primary_10_1016_j_jconrel_2019_08_034
crossref_primary_10_1111_cas_13552
crossref_primary_10_1080_10717544_2018_1461956
crossref_primary_10_1186_s12935_024_03469_0
crossref_primary_10_7717_peerj_17603
crossref_primary_10_1016_j_lfs_2016_12_007
crossref_primary_10_1016_j_biochi_2022_09_005
crossref_primary_10_1186_s13048_020_00689_6
crossref_primary_10_1007_s00261_021_03081_0
crossref_primary_10_2174_1568026619666190620155613
crossref_primary_10_1177_1179299X19860815
crossref_primary_10_1007_s00432_023_04831_x
crossref_primary_10_1021_acs_molpharmaceut_9b00136
crossref_primary_10_1021_acsami_7b15832
crossref_primary_10_1002_smll_202004975
crossref_primary_10_1089_cbr_2019_2824
crossref_primary_10_3389_fonc_2020_589601
crossref_primary_10_1007_s11010_022_04548_4
crossref_primary_10_1002_jcb_26814
crossref_primary_10_1021_acs_molpharmaceut_8b00024
crossref_primary_10_1002_kjm2_12546
crossref_primary_10_1039_D2BM01005D
crossref_primary_10_1016_j_jiec_2020_11_015
crossref_primary_10_1021_acsnano_8b08872
crossref_primary_10_1007_s40242_017_7090_1
crossref_primary_10_1016_j_tranon_2020_100987
crossref_primary_10_1186_s12871_021_01517_0
crossref_primary_10_1016_j_actbio_2021_02_007
crossref_primary_10_3892_ol_2017_5969
crossref_primary_10_3389_fcell_2021_747314
crossref_primary_10_1002_ijc_34150
crossref_primary_10_3389_fendo_2024_1489767
crossref_primary_10_1016_j_ijpharm_2020_119986
crossref_primary_10_1186_s13048_021_00859_0
crossref_primary_10_3390_pharmaceutics13071063
crossref_primary_10_1002_smll_202307462
crossref_primary_10_1007_s12032_023_02044_3
crossref_primary_10_3892_ol_2021_13102
crossref_primary_10_1097_AOG_0000000000002106
crossref_primary_10_1016_j_addr_2021_113969
crossref_primary_10_1007_s11095_022_03434_4
crossref_primary_10_1016_j_addr_2018_07_008
crossref_primary_10_1016_j_meomic_2023_100020
crossref_primary_10_3892_mco_2021_2343
crossref_primary_10_31260_RepertMedCir_01217372_1228
crossref_primary_10_1093_carcin_bgx054
crossref_primary_10_2147_OTT_S285153
crossref_primary_10_1186_s13048_019_0576_3
Cites_doi 10.1200/JCO.2005.04.8397
10.1016/j.ygyno.2009.01.012
10.1111/j.1365-2796.2011.02498.x
10.1126/science.1184208
10.1086/318787
10.1158/0008-5472.CAN-06-2030
10.1200/JCO.2012.42.0505
10.1093/annonc/mdt475
10.1016/j.cell.2012.02.028
10.1101/gad.2037511
10.1016/j.addr.2013.10.005
10.1056/NEJM197111182852108
10.1093/carcin/21.3.379
10.1073/pnas.0813371106
10.1073/pnas.172501499
10.1016/j.bmcl.2006.07.030
10.1158/1078-0432.CCR-12-1257
10.1038/nrg2905
10.1200/JCO.2008.16.0812
10.1126/science.3798106
10.1007/s11095-014-1436-x
10.1200/jco.2006.24.18_suppl.5026
10.1016/j.ygyno.2013.09.032
10.1016/j.jconrel.2009.06.019
10.1016/j.cell.2016.05.069
10.1073/pnas.1400821111
10.1016/j.ygyno.2003.08.021
10.1016/j.ejca.2008.12.013
10.1158/1078-0432.CCR-06-2878
10.1126/science.1076996
10.1016/j.ygyno.2013.03.002
10.1016/j.tig.2015.07.003
10.1016/j.ejphar.2015.10.058
10.5402/2012/245756
10.1186/1471-2407-11-453
10.1093/annonc/mdv250
10.1172/JCI85086
10.2217/nnm.11.131
10.1002/cncr.22774
10.1200/JCO.2010.30.5151
10.1056/NEJMra0802968
10.1586/14737159.5.2.221
10.1517/13543784.12.3.337
10.1159/000088478
10.1186/s12916-015-0278-7
10.1023/A:1023839319950
10.1016/j.ygyno.2005.06.040
10.3390/ijms140815885
10.1016/j.steroids.2013.01.008
10.1007/s11095-010-0235-2
10.1038/nbt.2038
10.1016/j.maturitas.2013.11.009
10.1158/1078-0432.CCR-13-1536
10.3389/fonc.2013.00296
10.1056/NEJMoa1104390
10.1038/cgt.2015.39
10.1124/jpet.105.084145
10.1002/(SICI)1097-0215(19970422)74:2<193::AID-IJC10>3.0.CO;2-F
10.1016/j.addr.2004.01.008
10.1023/A:1008317512253
10.1002/1097-0142(19951115)76:10+<2004::AID-CNCR2820761317>3.0.CO;2-G
10.1021/jm8001263
10.1016/S0168-3659(03)00209-8
10.1038/nature12627
10.1200/JCO.2011.39.8545
10.1089/scd.2006.0059
10.1016/S0925-4439(02)00096-0
10.1111/j.1471-0528.2010.02838.x
10.1056/NEJMoa021967
10.1016/j.cell.2015.04.044
10.1126/science.1198704
10.1016/j.ajog.2008.04.009
10.1016/j.addr.2016.06.016
10.1073/pnas.0530291100
10.1016/j.celrep.2012.08.003
10.1038/nrm1963
10.1097/PAS.0b013e3181cf3d79
10.1016/j.cell.2015.05.002
10.1016/j.ygyno.2012.11.036
10.1038/nm.3488
10.1038/bjc.1997.537
10.1038/jid.2013.248
10.1126/scitranslmed.3000702
10.1038/nmeth.1315
10.1021/mp070053o
10.1038/nature12172
10.1038/nmeth.2651
10.1016/j.biocel.2007.05.008
10.1093/nar/gkg703
10.1007/978-1-60761-609-2_19
10.3322/caac.21254
10.1007/s13402-011-0052-6
10.1016/j.maturitas.2009.01.001
10.1186/1476-4598-3-27
10.1016/j.bbrc.2005.05.132
10.1001/jama.2011.766
10.1016/j.cell.2009.05.051
10.2174/187152006778699095
10.1200/JCO.2013.49.7685
10.1016/j.ccr.2011.01.039
10.1016/j.addr.2013.09.017
10.1038/nrclinonc.2015.224
10.1073/pnas.082089499
10.2217/pgs.11.72
10.1038/bjc.2014.567
10.3389/fonc.2014.00322
10.1158/0008-5472.CAN-07-6307
10.1200/JCO.2005.05.4221
10.1016/j.ygyno.2009.02.009
10.1038/nature03443
10.2217/17435889.3.6.761
10.1038/nature07385
10.1002/ijc.25516
10.2217/fon.14.21
10.1038/onc.2014.291
10.1056/NEJMoa1105535
10.18773/austprescr.2012.052
10.1074/jbc.271.2.603
10.1038/nbt.2282
10.1038/nature09807
10.1200/JCO.2009.22.3354
10.1038/nrc1074
10.1200/JCO.2003.10.104
10.1056/NEJMoa1103799
10.1038/nrc2037
10.1016/j.molonc.2011.11.010
10.1016/S1535-6108(04)00083-2
10.1073/pnas.0504274102
10.1038/ng1570
10.1016/j.cell.2012.02.025
10.1126/science.1235122
10.1124/jpet.105.094243
ContentType Journal Article
Copyright 2016 The Authors
Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.
Copyright_xml – notice: 2016 The Authors
– notice: Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.
DBID 6I.
AAFTH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7S9
L.6
5PM
DOI 10.1016/j.jconrel.2016.10.014
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList AGRICOLA


MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1873-4995
EndPage 268
ExternalDocumentID PMC5191987
27746277
10_1016_j_jconrel_2016_10_014
S0168365916309695
Genre Journal Article
Review
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: R01 CA138533
GroupedDBID ---
--K
--M
.~1
0R~
1B1
1RT
1~.
1~5
4.4
457
4G.
53G
5GY
5VS
6I.
7-5
71M
8P~
9JM
AABNK
AABXZ
AACTN
AAEDT
AAEDW
AAFTH
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AATCM
AAXUO
ABFNM
ABFRF
ABJNI
ABMAC
ABOCM
ABYKQ
ABZDS
ACDAQ
ACGFO
ACGFS
ACIUM
ACRLP
ADBBV
ADEZE
AEBSH
AEFWE
AEKER
AENEX
AEZYN
AFKWA
AFRZQ
AFTJW
AFXIZ
AGHFR
AGUBO
AGYEJ
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
AXJTR
BKOJK
BLXMC
C45
CS3
DU5
EBS
EFJIC
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FIRID
FNPLU
FYGXN
G-Q
GBLVA
HMT
IHE
J1W
KOM
M34
M41
MO0
N9A
O-L
O9-
OAUVE
OGGZJ
OVD
OZT
P-8
P-9
P2P
PC.
Q38
RIG
RNS
ROL
RPZ
SCC
SDF
SDG
SDP
SES
SPC
SPCBC
SSM
SSP
SSZ
T5K
TEORI
~G-
.GJ
29K
3O-
AAHBH
AAQXK
AATTM
AAXKI
AAYOK
AAYWO
AAYXX
ABWVN
ABXDB
ACNNM
ACRPL
ACVFH
ADCNI
ADMUD
ADNMO
AEIPS
AEUPX
AFJKZ
AFPUW
AGCQF
AGQPQ
AGRNS
AHHHB
AIGII
AIIUN
AKBMS
AKRWK
AKYEP
ANKPU
APXCP
ASPBG
AVWKF
AZFZN
BNPGV
CITATION
D-I
FEDTE
FGOYB
G-2
HVGLF
HZ~
R2-
SEW
SPT
SSH
WUQ
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ACLOT
EFKBS
~HD
7S9
L.6
5PM
ID FETCH-LOGICAL-c570t-4c0529e4748b1706ce2f8f2788b35b90997a2b35e52644c2590b4696b59a6d6a3
IEDL.DBID AIKHN
ISSN 0168-3659
1873-4995
IngestDate Thu Aug 21 17:52:06 EDT 2025
Sun Sep 28 09:07:15 EDT 2025
Sun Sep 28 09:27:54 EDT 2025
Thu Apr 03 07:04:05 EDT 2025
Tue Jul 01 04:04:34 EDT 2025
Thu Apr 24 23:00:07 EDT 2025
Fri Feb 23 02:33:25 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords PARE
CDC
Targeted therapy
MIBI
PLD
PARP
MDA
SRM
LHRH
SNP
EMA
DOC
SNS
cDNA
PFS
ADCC
Genetic profiling
TDS
FRα
OS
P4
VEGF
qRT-PCR
mRNA-seq
siRNA
Personalized medicine
ER
MAB
QOL
WGA
PEG
HER
CEL-seq
NGS
Nanotechnology
Language English
License This is an open access article under the CC BY-NC-ND license.
Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c570t-4c0529e4748b1706ce2f8f2788b35b90997a2b35e52644c2590b4696b59a6d6a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
OpenAccessLink https://www.sciencedirect.com/science/article/pii/S0168365916309695
PMID 27746277
PQID 1835437366
PQPubID 23479
PageCount 19
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5191987
proquest_miscellaneous_2000238388
proquest_miscellaneous_1835437366
pubmed_primary_27746277
crossref_primary_10_1016_j_jconrel_2016_10_014
crossref_citationtrail_10_1016_j_jconrel_2016_10_014
elsevier_sciencedirect_doi_10_1016_j_jconrel_2016_10_014
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-12-10
PublicationDateYYYYMMDD 2016-12-10
PublicationDate_xml – month: 12
  year: 2016
  text: 2016-12-10
  day: 10
PublicationDecade 2010
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Journal of controlled release
PublicationTitleAlternate J Control Release
PublicationYear 2016
Publisher Elsevier B.V
Publisher_xml – name: Elsevier B.V
References Iinuma, Watanabe, Mimori, Adachi, Hayashi, Tamura, Matsuda, Fukushima, Okinaga, Sasako, Mori (bb0345) 2011; 29
Ledermann, Canevari, Thigpen (bb0630) 2015; 26
Thomas (bb0400) 1996; 271
Rosen, Wang, Atkinson, Yu, Lu, Diamandis, Hellstrom, Mok, Liu, Bast (bb0355) 2005; 99
Chow, Endersby, Zhu, Rankin, Qu, Zhang, Broniscer, Ellison, Baker (bb0065) 2011; 19
N. Cancer Genome Atlas Research (bb0840) 2008; 455
Wang, Zhang, Marzolf, Troisch, Brightman, Hu, Hood, Galas (bb0335) 2009; 106
Carmeliet (bb0405) 2005; 69
Saad, Garbuzenko, Minko (bb0795) 2008; 3
Tomczak, Czerwinska, Wiznerowicz (bb0835) 2015; 19
Minko (bb0780) 2013; 65
Burger, Brady, Bookman, Fleming, Monk, Huang, Mannel, Homesley, Fowler, Greer, Boente, Birrer, Liang (bb0430) 2011; 365
Minko, Rodriguez-Rodriguez, Pozharov (bb0765) 2013; 65
Eichbaum, Mayer, Eickoff, Bischofs, Gebauer, Fehm, Lenz, Fricke, Solomayer, Fersis, Schmidt, Wallwiener, Scheeweiss, Sohn (bb0475) 2011; 11
Minko, Patil, Zhang, Khandare, Saad, Chandna, Taratula (bb0785) 2010; 624
Picotti, Bodenmiller, Mueller, Domon, Aebersold (bb0210) 2009; 138
Verma (bb0175) 2015
J. Lopez, S. Banerjee, S.B. Kaye, New developments in the treatment of ovarian cancer–future perspectives, Ann. Oncol., 24 Suppl 10 (2013) x69-x76.
Perren, Swart, Pfisterer, Ledermann, Pujade-Lauraine, Kristensen, Carey, Beale, Cervantes, Kurzeder, Bois, Sehouli, Kimmig, Stahle, Collinson, Essapen, Gourley, Lortholary, Selle, Mirza, Leminen, Plante, Stark, Qian, Parmar, Oza (bb0435) 2011; 365
Schultz, Lopez, Saleh-Gohari, Helleday (bb0520) 2003; 31
Wang (bb0050) 2010
Dean, Hosono, Fang, Wu, Faruqi, Bray-Ward, Sun, Zong, Du, Du, Driscoll, Song, Kingsmore, Egholm, Lasken (bb0265) 2002; 99
Grada, Weinbrecht (bb0095) 2013; 133
Kamen (bb0575) 1997; 24
Naumann, Coleman, Burger, Sausville, Kutarska, Ghamande, Gabrail, Depasquale, Nowara, Gilbert, Gersh, Teneriello, Harb, Konstantinopoulos, Penson, Symanowski, Lovejoy, Leamon, Morgenstern, Messmann (bb0660) 2013; 31
Faulkner, Meldrum (bb0365) 2012; 35
Skates, Xu, Yu, Sjovall, Einhorn, Chang, Bast, Knapp (bb0360) 1995; 76
Dharap, Wang, Chandna, Khandare, Qiu, Gunaseelan, Sinko, Stein, Farmanfarmaian, Minko (bb0825) 2005; 102
Moya-Horno, Cortes (bb0685) 2015; Vol. 7
Gordon, Matei, Aghajanian, Matulonis, Brewer, Fleming, Hainsworth, Garcia, Pegram, Schilder, Cohn, Roman, Derynck, Ng, Lyons, Allison, Eberhard, Pham, Dere, Karlan (bb0695) 2006; 24
LUME-Ovar-1, LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer.
Siegel, Miller, Jemal (bb0010) 2015; 65
Buys, Partridge, Black, Johnson, Lamerato, Isaacs, Reding, Greenlee, Yokochi, Kessel, Crawford, Church, Andriole, Weissfeld, Fouad, Chia, O'Brien, Ragard, Clapp, Rathmell, Riley, Hartge, Pinsky, Zhu, Izmirlian, Kramer, Miller, Xu, Prorok, Gohagan, Berg, Team (bb0330) 2011; 305
Al-Hajj, Wicha, Benito-Hernandez, Morrison, Clarke (bb0225) 2003; 100
Liu, Lauffenburger (bb0055) 2009
Bedard, Hansen, Ratain, Siu (bb0240) 2013; 501
Chen, Chang, Huang, Chiang, Lin, Chen, Hsieh, Cheng (bb0625) 2012; 6
Whitemore, Gong, Itnyre (bb0105) 1997; 60
Minko, Pakunlu, Wang, Khandare, Saad (bb0805) 2006; 6
Chandna, Saad, Wang, Ber, Khandare, Vetcher, Soldatenkov, Minko (bb0800) 2007; 4
Navin, Kendall, Troge, Andrews, Rodgers, McIndoo, Cook, Stepansky, Levy, Esposito, Muthuswamy, Krasnitz, McCombie, Hicks, Wigler (bb0260) 2011; 472
Casillas, Fernandez, Camberos, Lopez, Pacheco, Velazquez (bb0350) 2014; 10
Dharap, Qiu, Williams, Sinko, Stein, Minko (bb0820) 2003; 91
Ashworth (bb0525) 2008; 26
Tanner, Hasenclever, Stern, Schormann, Bezler, Hermes, Brulport, Bauer, Schiffer, Gebhard, Schmidt, Steiner, Sehouli, Edelmann, Lauter, Lessig, Krishnamurthi, Ullrich, Hengstler (bb0715) 2006; 24
Tesaro, A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer.
Slamon, Clark, Wong, Levin, Ullrich, McGuire (bb0670) 1987; 235
Farley, Fuchiuji, Darcy, Tian, Hoskins, McGuire, Hanjani, Warshal, Greer, Belinson, Birrer (bb0675) 2009; 113
Dharap, Minko (bb0815) 2003; 20
Khan, Webb, Cadotte, Gavette (bb0220) 2015; 9
Zhang, Liu, Zhang, Payne, Zhang, McDermott, Zhou, Petyuk, Chen, Ray, Sun, Yang, Chen, Wang, Shah, Cha, Aiyetan, Woo, Tian, Gritsenko, Clauss, Choi, Monroe, Thomas, Nie, Wu, Moore, Yu, Tabb, Fenyo, Bafna, Wang, Rodriguez, Boja, Hiltke, Rivers, Sokoll, Zhu, Ie, Cope, Pandey, Zhang, Snyder, Levine, Smith, Chan, Rodland (bb0185) 2016; 166
Macosko, Basu, Satija, Nemesh, Shekhar, Goldman, Tirosh, Bialas, Kamitaki, Martersteck, Trombetta, Weitz, Sanes, Shalek, Regev, McCarroll (bb0310) 2015; 161
Shaw, Hall (bb0535) 2013; 6
Amstutz, Froehlich, Largiader (bb0590) 2011; 12
Pujade-Lauraine, Hilpert, Weber (bb0450) 2012
Crane, Arts, van Oosten, Low, van der Zee, van Dam, Bart (bb0615) 2012; 35
Kurman, Shih (bb0025) 2010; 34
Tang, Barbacioru, Wang, Nordman, Lee, Xu, Wang, Bodeau, Tuch, Siddiqui, Lao, Surani (bb0280) 2009; 6
Kaluzna, Strauss, Zajac-Spychala, Gowin, Swiatek-Koscielna, Nowak, Fichna, Mankowski, Januszkiewicz-Lewandowska (bb0595) 2015; 769
Simpkins, Hevia-Paez, Sun, Ullmer, Gilbert, da Silva, Pedram, Levin, Reis, Rabinovich, Azzam, Xu, Ince, Yang, Verhaak, Lu, Mills, Slingerland (bb0725) 2012; 18
Dietel, Johrens, Laffert, Hummel, Blaker, Pfitzner, Lehmann, Denkert, Darb-Esfahani, Lenze, Heppner, Koch, Sers, Klauschen, Anagnostopoulos (bb0115) 2015; 22
Argenta, Thomas, Judson, Downs, Geller, Carson, Jonson, Ghebre (bb0735) 2009; 113
Balduzzi, Mantarro, Guarneri, Tagliabue, Pistotti, Moja, D'Amico (bb0680) 2014; 18
Gavalas, Liontos, Trachana, Bagratuni, Arapinis, Liacos, Dimopoulos, Bamias (bb0395) 2013; 14
AURELIA, AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer. Vol. 12.05.15.
Risch, McLaughlin, Cole, Rosen, Bradley, Kwan, Jack, Vesprini, Kuperstein, Abrahamson, Fan, Wong (bb0110) 2001; 68
Makhija, Amler, Glenn, Ueland, Gold, Dizon, Paton, Lin, Januario, Ng, Strauss, Kelsey, Sliwkowski, Matulonis (bb0700) 2010; 28
Simpkins, Garcia-Soto, Slingerland (bb0730) 2013; 78
H.-L. Roche, A Study of Pertuzumab in Combination With Standard Chemotherapy in Women With Recurrent Platinum-Resistant Epithelian Ovarian Cancer and Low HER3 mRNA Expression.
Warrenfeltz, Pavlik, Datta, Kraemer, Benigno, McDonald (bb0140) 2004; 3
Vlahov, Santhapuram, Kleindl, Howard, Stanford, Leamon (bb0650) 2006; 16
Haemmerle, Bottsford-Miller, Pradeep, Taylor, Choi, Hansen, Dalton, Stone, Cho, Nick, Nagaraja, Gutschner, Gharpure, Mangala, Rupaimoole, Han, Zand, Armaiz-Pena, Wu, Pecot, Burns, Lopez-Berestein, Afshar-Kharghan, Sood (bb0385) 2016; 126
Yamamoto, Konishi, Mandai, Kuroda, Komatsu, Nanbu, Sakahara, Mori (bb0415) 1997; 76
Ledermann, Harter, Gourley, Friedlander, Vergote, Rustin, Scott, Meier, Shapira-Frommer, Safra, Matei, Macpherson, Watkins, Carmichael, Matulonis (bb0545) 2012; 366
Foulkes (bb0090) 2008; 359
Singh, Clarke, Terasaki, Bonn, Hawkins, Squire, Dirks (bb0235) 2003; 63
Bookman, Darcy, Clarke-Pearson, Boothby, Horowitz (bb0690) 2003; 21
Ledermann, Perren, Raja, Embleton, Rustin, Jayson, Kaye, Swart, Vaughan, Hirte (bb0500) 2013
Miller, Jackson (bb0740) 2003; 12
Leary, Kinde, Diehl, Schmidt, Clouser, Duncan, Antipova, Lee, McKernan, De La Vega, Kinzler, Vogelstein, Diaz, Velculescu (bb0120) 2010; 2
Aghajanian, Blank, Goff, Judson, Teneriello, Husain, Sovak, Yi, Nycum (bb0440) 2012; 30
Saadatpour, Lai, Guo, Yuan (bb0300) 2015; 31
Verma, Alhayki, Le, Balnes, Rambout, Hopkins (bb0760) 2006; 24
Xu, Hou, Yin, Bao, Tang, Song, Li, Tsang, Wu, Wu, He, Zeng, Xing, Wu, Jiang, Liu, Cao, Guo, Hu, Gui, Li, Xie, Sun, Shi, Cai, Wang, Zhong, Li, Lu, Gu, Zhang, Goodman, Bolund, Wang, Yang, Kristiansen, Dean, Li, Wang (bb0275) 2012; 148
Lin, Hassan, Li, Zhao, Nooka, Sorenson, Xie, Champlin, Wu, Li (bb0340) 2007; 110
Bryant, Schultz, Thomas, Parker, Flower, Lopez, Kyle, Meuth, Curtin, Helleday (bb0515) 2005; 434
Arora, Scholar (bb0465) 2005; 315
Luco, Pan, Tominaga, Blencowe, Pereira-Smith, Misteli (bb0165) 2010; 327
Shalek, Satija, Adiconis, Gertner, Gaublomme, Raychowdhury, Schwartz, Yosef, Malboeuf, Lu, Trombetta, Gennert, Gnirke, Goren, Hacohen, Levin, Park, Regev (bb0295) 2013; 498
Lombardi (bb0755) 2002; 1587
Li, Heidt, Dalerba, Burant, Zhang, Adsay, Wicha, Clarke, Simeone (bb0230) 2007; 67
Konstantinopoulos, Matulonis (bb0075) 2013; 3
Savla, Minko (bb0200) 2016
Dalerba, Kalisky, Sahoo, Rajendran, Rothenberg, Leyrat, Sim, Okamoto, Johnston, Qian, Zabala, Bueno, Neff, Wang, Shelton, Visser, Hisamori, Shimono, Van De Wetering, Clevers, Clarke, Quake (bb0285) 2012; 29
Franklin, Carey, Vajdos, Leahy, de Vos, Sliwkowski (bb0710) 2004; 5
Ramskold, Luo, Wang, Li, Deng, Faridani, Daniels, Khrebtukova, Loring, Laurent, Schroth, Sandberg (bb0290) 2012; 30
ICON6, An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer (ICON6).
GSK, Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women.
Chandna, Khandare, Ber, Rodriguez-Rodriguez, Minko (bb0790) 2010; 27
Chen, Zhuang, Lin, Yu, Wang, Shi, Hu, Sun (bb0035) 2015; 13
Smyth, Gourley, Walker, MacKean, Stevenson, Williams, Nafussi, Rye, Rye, Stewart, McCurdy, Mano, Reed, McMahon, Vasey, Gabra, Langdon (bb0750) 2007; 13
Nossov, Amneus, Su, Lang, Janco, Reddy, Farias-Eisner (bb0370) 2008; 199
Stahlberg, Zoric, Aman, Kubista (bb0130) 2005; 5
Folkman (bb0390) 1971; 285
Ohman, Hasan, Dinulescu (bb0190) 2014; 4
Menear, Adcock, Boulter, Cockcroft, Copsey, Cranston, Dillion, Drzewiecki, Garman, Gomez, Javaid, Kerrigan, Knights, Lau, Loh, Matthews, Moore, O'Connor, Smith, Martin (bb0530) 2008; 51
Bendall, Simonds, Qiu, el, Krutzik, Finck, Bruggner, Melamed, Trejo, Ornatsky, Balderas, Plevritis, Sachs, Pe'er, Tanner, Nolan (bb0320) 2011; 332
Rajagopalan, Zhang, McCourt, Dwyer, Benkovic, Hammes (bb0580) 2002; 99
Klein, Mazutis, Akartuna, Tallapragada, Veres, Li, Peshkin, Weitz, Kirschner (bb0315) 2015; 161
M. Pharmaceuticals, A Study of MM-121 With Paclitaxel
10.1016/j.jconrel.2016.10.014_bb0455
Buys (10.1016/j.jconrel.2016.10.014_bb0330) 2011; 305
Tian (10.1016/j.jconrel.2016.10.014_bb0040) 2012; 271
Rajagopalan (10.1016/j.jconrel.2016.10.014_bb0580) 2002; 99
Schultz (10.1016/j.jconrel.2016.10.014_bb0520) 2003; 31
Gavalas (10.1016/j.jconrel.2016.10.014_bb0395) 2013; 14
Gordon (10.1016/j.jconrel.2016.10.014_bb0695) 2006; 24
Simpkins (10.1016/j.jconrel.2016.10.014_bb0725) 2012; 18
Zhang (10.1016/j.jconrel.2016.10.014_bb0185) 2016; 166
Pujade-Lauraine (10.1016/j.jconrel.2016.10.014_bb0450) 2012
Miller (10.1016/j.jconrel.2016.10.014_bb0740) 2003; 12
Dalerba (10.1016/j.jconrel.2016.10.014_bb0285) 2012; 29
Chow (10.1016/j.jconrel.2016.10.014_bb0065) 2011; 19
Balduzzi (10.1016/j.jconrel.2016.10.014_bb0680) 2014; 18
Bedard (10.1016/j.jconrel.2016.10.014_bb0240) 2013; 501
Dharap (10.1016/j.jconrel.2016.10.014_bb0810) 2006; 316
Picotti (10.1016/j.jconrel.2016.10.014_bb0210) 2009; 138
Aghajanian (10.1016/j.jconrel.2016.10.014_bb0445) 2012
Khan (10.1016/j.jconrel.2016.10.014_bb0220) 2015; 9
10.1016/j.jconrel.2016.10.014_bb0565
10.1016/j.jconrel.2016.10.014_bb0720
Longley (10.1016/j.jconrel.2016.10.014_bb0585) 2003; 3
Ledermann (10.1016/j.jconrel.2016.10.014_bb0545) 2012; 366
Ramskold (10.1016/j.jconrel.2016.10.014_bb0290) 2012; 30
Haemmerle (10.1016/j.jconrel.2016.10.014_bb0385) 2016; 126
Chen (10.1016/j.jconrel.2016.10.014_bb0625) 2012; 6
Bianco (10.1016/j.jconrel.2016.10.014_bb0215) 2007; 39
Kobel (10.1016/j.jconrel.2016.10.014_bb0620) 2014; 111
Kaluzna (10.1016/j.jconrel.2016.10.014_bb0595) 2015; 769
Ledermann (10.1016/j.jconrel.2016.10.014_bb0630) 2015; 26
Siegel (10.1016/j.jconrel.2016.10.014_bb0010) 2015; 65
A.C. Society (10.1016/j.jconrel.2016.10.014_bb0080) 2015; 2015
Xu (10.1016/j.jconrel.2016.10.014_bb0275) 2012; 148
Du (10.1016/j.jconrel.2016.10.014_bb0045) 2015; 34
10.1016/j.jconrel.2016.10.014_bb0570
A.C. Society (10.1016/j.jconrel.2016.10.014_bb0015) 2014; Vol. 2015
Klein (10.1016/j.jconrel.2016.10.014_bb0315) 2015; 161
Dharap (10.1016/j.jconrel.2016.10.014_bb0815) 2003; 20
Nicholas (10.1016/j.jconrel.2016.10.014_bb0250) 2007; 16
Rosen (10.1016/j.jconrel.2016.10.014_bb0355) 2005; 99
Schreiber (10.1016/j.jconrel.2016.10.014_bb0510) 2006; 7
Barillot (10.1016/j.jconrel.2016.10.014_bb0060) 2012
Grada (10.1016/j.jconrel.2016.10.014_bb0095) 2013; 133
Argenta (10.1016/j.jconrel.2016.10.014_bb0735) 2009; 113
Verma (10.1016/j.jconrel.2016.10.014_bb0175) 2015
Aerts (10.1016/j.jconrel.2016.10.014_bb0135) 2001; 12
Toffoli (10.1016/j.jconrel.2016.10.014_bb0610) 1997; 74
Ferrara (10.1016/j.jconrel.2016.10.014_bb0425) 2005; 333
Yan (10.1016/j.jconrel.2016.10.014_bb0145) 2015
Johnson (10.1016/j.jconrel.2016.10.014_bb0655) 1963; Vol. 20
10.1016/j.jconrel.2016.10.014_bb0640
10.1016/j.jconrel.2016.10.014_bb0485
Slamon (10.1016/j.jconrel.2016.10.014_bb0670) 1987; 235
Lombardi (10.1016/j.jconrel.2016.10.014_bb0755) 2002; 1587
Moshehi (10.1016/j.jconrel.2016.10.014_bb0100) 2000; 66
Thorsen (10.1016/j.jconrel.2016.10.014_bb0255) 2002; 298
Saadatpour (10.1016/j.jconrel.2016.10.014_bb0300) 2015; 31
Verma (10.1016/j.jconrel.2016.10.014_bb0760) 2006; 24
Simpkins (10.1016/j.jconrel.2016.10.014_bb0730) 2013; 78
Tanner (10.1016/j.jconrel.2016.10.014_bb0715) 2006; 24
Ashworth (10.1016/j.jconrel.2016.10.014_bb0525) 2008; 26
Casillas (10.1016/j.jconrel.2016.10.014_bb0350) 2014; 10
Chandna (10.1016/j.jconrel.2016.10.014_bb0800) 2007; 4
Macosko (10.1016/j.jconrel.2016.10.014_bb0310) 2015; 161
Crane (10.1016/j.jconrel.2016.10.014_bb0615) 2012; 35
Savla (10.1016/j.jconrel.2016.10.014_bb0200) 2016
Leamon (10.1016/j.jconrel.2016.10.014_bb0645) 2004; 56
Hilberg (10.1016/j.jconrel.2016.10.014_bb0470) 2008; 68
Ricciardelli (10.1016/j.jconrel.2016.10.014_bb0030) 2009; 62
Foulkes (10.1016/j.jconrel.2016.10.014_bb0090) 2008; 359
Ghosh (10.1016/j.jconrel.2016.10.014_bb0195) 2014; 111
Hagemann (10.1016/j.jconrel.2016.10.014_bb0605) 2013; 131
Chen (10.1016/j.jconrel.2016.10.014_bb0035) 2015; 13
Deaton (10.1016/j.jconrel.2016.10.014_bb0160) 2011; 25
Moya-Horno (10.1016/j.jconrel.2016.10.014_bb0685) 2015; Vol. 7
Loeb (10.1016/j.jconrel.2016.10.014_bb0020) 2000; 21
Skates (10.1016/j.jconrel.2016.10.014_bb0360) 1995; 76
Faulkner (10.1016/j.jconrel.2016.10.014_bb0365) 2012; 35
Dharap (10.1016/j.jconrel.2016.10.014_bb0820) 2003; 91
Vergote (10.1016/j.jconrel.2016.10.014_bb0600) 2009; 45
Luco (10.1016/j.jconrel.2016.10.014_bb0165) 2010; 327
Kamen (10.1016/j.jconrel.2016.10.014_bb0575) 1997; 24
Bandiera (10.1016/j.jconrel.2016.10.014_bb0410) 2012; 2012
Yamamoto (10.1016/j.jconrel.2016.10.014_bb0415) 1997; 76
Zhou (10.1016/j.jconrel.2016.10.014_bb0170) 2011; 12
Amstutz (10.1016/j.jconrel.2016.10.014_bb0590) 2011; 12
Vogelstein (10.1016/j.jconrel.2016.10.014_bb0155) 2013; 339
Folkman (10.1016/j.jconrel.2016.10.014_bb0390) 1971; 285
Eichbaum (10.1016/j.jconrel.2016.10.014_bb0475) 2011; 11
Shah (10.1016/j.jconrel.2016.10.014_bb0775) 2013; 19
Stahlberg (10.1016/j.jconrel.2016.10.014_bb0130) 2005; 5
Nossov (10.1016/j.jconrel.2016.10.014_bb0370) 2008; 199
Alsop (10.1016/j.jconrel.2016.10.014_bb0085) 2012; 30
10.1016/j.jconrel.2016.10.014_bb0125
Minko (10.1016/j.jconrel.2016.10.014_bb0805) 2006; 6
Thomas (10.1016/j.jconrel.2016.10.014_bb0400) 1996; 271
Narod (10.1016/j.jconrel.2016.10.014_bb0380) 2016; 13
Bendall (10.1016/j.jconrel.2016.10.014_bb0320) 2011; 332
Leary (10.1016/j.jconrel.2016.10.014_bb0120) 2010; 2
Smyth (10.1016/j.jconrel.2016.10.014_bb0750) 2007; 13
Liu (10.1016/j.jconrel.2016.10.014_bb0055) 2009
Carmeliet (10.1016/j.jconrel.2016.10.014_bb0405) 2005; 69
Bookman (10.1016/j.jconrel.2016.10.014_bb0690) 2003; 21
N. Cancer Genome Atlas Research (10.1016/j.jconrel.2016.10.014_bb0840) 2008; 455
Bryant (10.1016/j.jconrel.2016.10.014_bb0515) 2005; 434
Makhija (10.1016/j.jconrel.2016.10.014_bb0700) 2010; 28
Chandna (10.1016/j.jconrel.2016.10.014_bb0790) 2010; 27
Taratula (10.1016/j.jconrel.2016.10.014_bb0830) 2009; 140
Warrenfeltz (10.1016/j.jconrel.2016.10.014_bb0140) 2004; 3
Keita (10.1016/j.jconrel.2016.10.014_bb0180) 2013; 128
Shalek (10.1016/j.jconrel.2016.10.014_bb0295) 2013; 498
Naumann (10.1016/j.jconrel.2016.10.014_bb0660) 2013; 31
Tang (10.1016/j.jconrel.2016.10.014_bb0280) 2009; 6
Wang (10.1016/j.jconrel.2016.10.014_bb0335) 2009; 106
10.1016/j.jconrel.2016.10.014_bb0490
Schmid (10.1016/j.jconrel.2016.10.014_bb0420) 2014; 77
10.1016/j.jconrel.2016.10.014_bb0495
Wang (10.1016/j.jconrel.2016.10.014_bb0050) 2010
Zbuk (10.1016/j.jconrel.2016.10.014_bb0070) 2007; 7
10.1016/j.jconrel.2016.10.014_bb0375
Vlahov (10.1016/j.jconrel.2016.10.014_bb0650) 2006; 16
Navin (10.1016/j.jconrel.2016.10.014_bb0260) 2011; 472
Menear (10.1016/j.jconrel.2016.10.014_bb0530) 2008; 51
Minko (10.1016/j.jconrel.2016.10.014_bb0785) 2010; 624
Burger (10.1016/j.jconrel.2016.10.014_bb0430) 2011; 365
Dharap (10.1016/j.jconrel.2016.10.014_bb0825) 2005; 102
10.1016/j.jconrel.2016.10.014_bb0555
Risch (10.1016/j.jconrel.2016.10.014_bb0110) 2001; 68
duBois (10.1016/j.jconrel.2016.10.014_bb0480) 2013; Vol. 31
Dean (10.1016/j.jconrel.2016.10.014_bb0265) 2002; 99
van de Vijver (10.1016/j.jconrel.2016.10.014_bb0150) 2002; 347
Ferlay (10.1016/j.jconrel.2016.10.014_bb0005) 2010; 127
Hartmann (10.1016/j.jconrel.2016.10.014_bb0460) 2009; Vol. 10
Arora (10.1016/j.jconrel.2016.10.014_bb0465) 2005; 315
Minko (10.1016/j.jconrel.2016.10.014_bb0780) 2013; 65
Perren (10.1016/j.jconrel.2016.10.014_bb0435) 2011; 365
Zhang (10.1016/j.jconrel.2016.10.014_bb0770) 2012; 7
Ohman (10.1016/j.jconrel.2016.10.014_bb0190) 2014; 4
Ledermann (10.1016/j.jconrel.2016.10.014_bb0500) 2013
Ledermann (10.1016/j.jconrel.2016.10.014_bb0540) 2013
Singh (10.1016/j.jconrel.2016.10.014_bb0235) 2003; 63
Shaw (10.1016/j.jconrel.2016.10.014_bb0535) 2013; 6
Konstantinopoulos (10.1016/j.jconrel.2016.10.014_bb0075) 2013; 3
Al-Hajj (10.1016/j.jconrel.2016.10.014_bb0225) 2003; 100
Iinuma (10.1016/j.jconrel.2016.10.014_bb0345) 2011; 29
Kurman (10.1016/j.jconrel.2016.10.014_bb0025) 2010; 34
10.1016/j.jconrel.2016.10.014_bb0560
Armstrong (10.1016/j.jconrel.2016.10.014_bb0635) 2013; 129
Whitemore (10.1016/j.jconrel.2016.10.014_bb0105) 1997; 60
Franklin (10.1016/j.jconrel.2016.10.014_bb0710) 2004; 5
Dietel (10.1016/j.jconrel.2016.10.014_bb0115) 2015; 22
Saad (10.1016/j.jconrel.2016.10.014_bb0795) 2008; 3
10.1016/j.jconrel.2016.10.014_bb0665
10.1016/j.jconrel.2016.10.014_bb0705
Li (10.1016/j.jconrel.2016.10.014_bb0230) 2007; 67
Hou (10.1016/j.jconrel.2016.10.014_bb0270) 2012; 148
Lin (10.1016/j.jconrel.2016.10.014_bb0340) 2007; 110
Aghajanian (10.1016/j.jconrel.2016.10.014_bb0440) 2012; 30
Mukhopadhyay (10.1016/j.jconrel.2016.10.014_bb0505) 2011; 118
Minko (10.1016/j.jconrel.2016.10.014_bb0765) 2013; 65
Hashimshony (10.1016/j.jconrel.2016.10.014_bb0305) 2012; 2
Farley (10.1016/j.jconrel.2016.10.014_bb0675) 2009; 113
Tomczak (10.1016/j.jconrel.2016.10.014_bb0835) 2015; 19
Hofree (10.1016/j.jconrel.2016.10.014_bb0245) 2013; 10
10.1016/j.jconrel.2016.10.014_bb0550
Savla (10.1016/j.jconrel.2016.10.014_bb0205) 2014; 31
Angelo (10.1016/j.jconrel.2016.10.014_bb0325) 2014; 20
del Carmen (10.1016/j.jconrel.2016.10.014_bb0745) 2003; 91
12930944 - Nucleic Acids Res. 2003 Sep 1;31(17):4959-64
23856935 - J Invest Dermatol. 2013 Aug;133(8):e11
21422427 - J Clin Oncol. 2011 Apr 20;29(12 ):1547-55
18800822 - J Med Chem. 2008 Oct 23;51(20):6581-91
19567257 - J Control Release. 2009 Dec 16;140(3):284-93
16061277 - Gynecol Oncol. 2005 Nov;99(2):267-77
15471544 - Mol Cancer. 2004 Oct 07;3:27
11249047 - Ann Oncol. 2001 Jan;12(1):39-46
12605559 - Expert Opin Investig Drugs. 2003 Mar;12(3):337-51
15093539 - Cancer Cell. 2004 Apr;5(4):317-28
24120655 - Adv Drug Deliv Rev. 2013 Nov;65(13-14):1880-95
24265409 - Ann Oncol. 2013 Dec;24 Suppl 10:x69-x76
21397855 - Cancer Cell. 2011 Mar 8;19(3):305-16
18591545 - J Clin Oncol. 2008 Aug 1;26(22):3785-90
19246379 - Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4402-7
14522905 - Cancer Res. 2003 Sep 15;63(18):5821-8
10739756 - Am J Hum Genet. 2000 Apr;66(4):1259-72
20371490 - Sci Transl Med. 2010 Feb 24;2(20):20ra14
12817893 - Pharm Res. 2003 Jun;20(6):889-96
8634992 - Cancer. 1995 Nov 15;76(10 Suppl):2004-10
9133455 - Int J Cancer. 1997 Apr 22;74(2):193-8
21647742 - Cell Oncol (Dordr). 2012 Feb;35(1):9-18
22939981 - Cell Rep. 2012 Sep 27;2(3):666-73
24048068 - Nature. 2013 Sep 19;501(7467):355-64
18468571 - Am J Obstet Gynecol. 2008 Sep;199(3):215-23
22014006 - BMC Cancer. 2011 Oct 20;11:453
16002463 - J Pharmacol Exp Ther. 2005 Dec;315(3):971-9
15833051 - Expert Rev Mol Diagn. 2005 Mar;5(2):221-30
26056489 - Breast Cancer (Dove Med Press). 2015 May 21;7:125-32
24584119 - Nat Med. 2014 Apr;20(4):436-42
10688858 - Carcinogenesis. 2000 Mar;21(3):379-85
24037242 - Nat Methods. 2013 Nov;10(11):1108-15
12490681 - N Engl J Med. 2002 Dec 19;347(25):1999-2009
21576262 - Genes Dev. 2011 May 15;25(10):1010-22
12629218 - Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8
21919607 - Pharmacogenomics. 2011 Sep;12(9):1321-36
9042908 - Am J Hum Genet. 1997 Mar;60(3):496-504
17167516 - Nat Rev Cancer. 2007 Jan;7(1):35-45
21399628 - Nature. 2011 Apr 7;472(7341):90-4
17100558 - Anticancer Agents Med Chem. 2006 Nov;6(6):537-52
22820318 - Nat Biotechnol. 2012 Aug;30(8):777-82
19664813 - Cell. 2009 Aug 21;138(4):795-806
24377084 - Front Oncol. 2013 Dec 11;3:296
24380827 - Maturitas. 2014 Feb;77(2):128-36
24919932 - Pharm Res. 2014 Dec;31(12 ):3487-502
22529265 - J Clin Oncol. 2012 Jun 10;30(17):2039-45
20154587 - Am J Surg Pathol. 2010 Mar;34(3):433-43
3798106 - Science. 1987 Jan 9;235(4785):177-82
12084475 - Biochim Biophys Acta. 2002 Jul 18;1587(2-3):326-37
24177352 - Adv Drug Deliv Rev. 2013 Nov;65(13-14):1665-6
26358176 - Cancer Gene Ther. 2015 Sep;22(9):417-30
19025451 - Nanomedicine (Lond). 2008 Dec;3(6):761-76
24043945 - Onco Targets Ther. 2013 Sep 03;6:1197-206
16896006 - J Clin Oncol. 2006 Sep 10;24(26):4324-32
17283135 - Cancer Res. 2007 Feb 1;67(3):1030-7
23539594 - Science. 2013 Mar 29;339(6127):1546-58
15094211 - Adv Drug Deliv Rev. 2004 Apr 29;56(8):1127-41
22711857 - J Clin Oncol. 2012 Jul 20;30(21):2654-63
26063635 - Ann Oncol. 2015 Oct;26(10):2034-43
17596994 - Int J Biochem Cell Biol. 2007;39(7-8):1416-31
15829966 - Nature. 2005 Apr 14;434(7035):913-7
21551058 - Science. 2011 May 6;332(6030):687-96
16301830 - Oncology. 2005;69 Suppl 3:4-10
16829982 - Nat Rev Mol Cell Biol. 2006 Jul;7(7):517-28
22142401 - J Intern Med. 2012 Feb;271(2):111-21
14070392 - Cancer Res. 1963 Sep;23:1390-427
22204725 - N Engl J Med. 2011 Dec 29;365(26):2484-96
21351269 - Int J Cancer. 2010 Dec 15;127(12):2893-917
27372738 - Cell. 2016 Jul 28;166(3):755-65
12525520 - J Clin Oncol. 2003 Jan 15;21(2):283-90
21642681 - JAMA. 2011 Jun 8;305(22):2295-303
23219462 - Gynecol Oncol. 2013 Feb;128(2):356-63
12359872 - Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13481-6
17575226 - Clin Cancer Res. 2007 Jun 15;13(12):3617-22
25478323 - Front Oncol. 2014 Nov 18;4:322
18559524 - Cancer Res. 2008 Jun 15;68(12):4774-82
23903048 - Int J Mol Sci. 2013 Jul 30;14(8):15885-909
15961063 - Biochem Biophys Res Commun. 2005 Jul 29;333(2):328-35
25214538 - Proc Natl Acad Sci U S A. 2014 Sep 23;111(38):13948-53
17594720 - Cancer. 2007 Aug 1;110(3):534-42
12351675 - Science. 2002 Oct 18;298(5593):580-4
16291730 - J Pharmacol Exp Ther. 2006 Mar;316(3):992-8
19239974 - Gynecol Oncol. 2009 May;113(2):205-9
24096113 - Gynecol Oncol. 2013 Dec;131(3):535-40
22385958 - Cell. 2012 Mar 2;148(5):886-95
19901115 - J Clin Oncol. 2010 Mar 1;28(7):1215-23
11959976 - Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5261-6
27374457 - Adv Drug Deliv Rev. 2016 Jun 29;:null
22204724 - N Engl J Med. 2011 Dec 29;365(26):2473-83
23402742 - Steroids. 2013 Jun;78(6):530-7
19272639 - Gynecol Oncol. 2009 Jun;113(3):341-7
17348809 - Stem Cells Dev. 2007 Feb;16(1):109-17
24036854 - Clin Cancer Res. 2013 Nov 15;19(22):6193-204
9420019 - Semin Oncol. 1997 Oct;24(5 Suppl 18):S18-30-S18-39
22081019 - Nat Biotechnol. 2011 Nov 13;29(12):1120-7
19193504 - Maturitas. 2009 Mar 20;62(3):270-5
25349970 - Br J Cancer. 2014 Dec 9;111(12):2297-307
8557658 - J Biol Chem. 1996 Jan 12;271(2):603-6
16896008 - J Clin Oncol. 2006 Sep 10;24(26):4317-23
26344672 - Epigenomics. 2016 Jan;8(1):119-33
16870437 - Bioorg Med Chem Lett. 2006 Oct 1;16(19):5093-6
22265591 - Mol Oncol. 2012 Jun;6(3):360-9
27064283 - J Clin Invest. 2016 May 2;126(5):1885-96
20217603 - Methods Mol Biol. 2010;624:281-94
26000487 - Cell. 2015 May 21;161(5):1187-201
19689244 - Curr Drug Metab. 2009 Jun;10(5):470-81
25691825 - Contemp Oncol (Pozn). 2015;19(1A):A68-77
23474348 - Gynecol Oncol. 2013 Jun;129(3):452-8
26000488 - Cell. 2015 May 21;161(5):1202-14
17685579 - Mol Pharm. 2007 Sep-Oct;4(5):668-78
9365173 - Br J Cancer. 1997;76(9):1221-7
25857315 - BMC Med. 2015 Mar 05;13:45
26450340 - Trends Genet. 2015 Oct;31(10):576-86
19168349 - Eur J Cancer. 2009 May;45(8):1415-23
15920528 - Nat Genet. 2005 Jun;37 Suppl:S31-7
12932638 - J Control Release. 2003 Aug 28;91(1-2):61-73
22385957 - Cell. 2012 Mar 2;148(5):873-85
4938153 - N Engl J Med. 1971 Nov 18;285(21):1182-6
22792477 - ISRN Obstet Gynecol. 2012;2012:245756
24127448 - J Clin Oncol. 2013 Dec 10;31(35):4400-6
12724731 - Nat Rev Cancer. 2003 May;3(5):330-8
16123131 - Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12962-7
26528799 - Eur J Pharmacol. 2015 Dec 15;769:93-9
26309409 - Breast Cancer (Auckl). 2015 Aug 10;9(Suppl 2):1-5
24919460 - Cochrane Database Syst Rev. 2014 Jun 12;(6):CD006242
18772890 - Nature. 2008 Oct 23;455(7216):1061-8
25052758 - Future Oncol. 2014 Jun;10(8):1501-13
26787282 - Nat Rev Clin Oncol. 2016 Apr;13(4):255-61
11179017 - Am J Hum Genet. 2001 Mar;68(3):700-10
19005198 - N Engl J Med. 2008 Nov 13;359(20):2143-53
22452356 - N Engl J Med. 2012 Apr 12;366(15):1382-92
22339132 - Nanomedicine (Lond). 2012 Feb;7(2):185-97
21244617 - BJOG. 2011 Mar;118(4):429-32
20133523 - Science. 2010 Feb 19;327(5968):996-1000
19349980 - Nat Methods. 2009 May;6(5):377-82
25559415 - CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
14675683 - Gynecol Oncol. 2003 Dec;91(3):596-602
25220419 - Oncogene. 2015 Jun;34(25):3215-25
23685454 - Nature. 2013 Jun 13;498(7453):236-40
21116306 - Nat Rev Genet. 2011 Jan;12(1):7-18
20700631 - Pharm Res. 2010 Nov;27(11):2296-306
22896656 - Clin Cancer Res. 2012 Nov 1;18(21):5911-23
References_xml – volume: 29
  start-page: 1547
  year: 2011
  end-page: 1555
  ident: bb0345
  article-title: Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer
  publication-title: J. Clin. Oncol.
– volume: 24
  start-page: 4324
  year: 2006
  end-page: 4332
  ident: bb0695
  article-title: Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status
  publication-title: J. Clin. Oncol.
– volume: 6
  start-page: 537
  year: 2006
  end-page: 552
  ident: bb0805
  article-title: New generation of liposomal drugs for cancer
  publication-title: Anti Cancer Agents Med. Chem.
– volume: 2
  year: 2010
  ident: bb0120
  article-title: Development of personalized tumor biomarkers using massively parallel sequencing
  publication-title: Sci. Transl. Med.
– volume: 21
  start-page: 283
  year: 2003
  end-page: 290
  ident: bb0690
  article-title: Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the gynecologic oncology group
  publication-title: J. Clin. Oncol.
– volume: 6
  start-page: 1197
  year: 2013
  end-page: 1206
  ident: bb0535
  article-title: Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib
  publication-title: Onco. Targets Ther.
– volume: Vol. 10
  start-page: 470
  year: 2009
  end-page: 481
  ident: bb0460
  article-title: Tyrosine Kinase Inhibitors - A Review on Pharmacology, Metabolism, and Side Effects
– year: 2010
  ident: bb0050
  article-title: Cancer Systems Biology
– volume: 347
  start-page: 1999
  year: 2002
  end-page: 2009
  ident: bb0150
  article-title: A Gene-expression signature as a predictor of survival in breast cancer
  publication-title: N. Engl. J. Med.
– reference: Abbott, Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation (Veli-BRCA).
– volume: 51
  start-page: 6581
  year: 2008
  end-page: 6591
  ident: bb0530
  article-title: 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one - a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1
  publication-title: J. Med. Chem.
– volume: 339
  start-page: 1546
  year: 2013
  end-page: 1558
  ident: bb0155
  article-title: Cancer genome landscapes
  publication-title: Science
– volume: 472
  start-page: 90
  year: 2011
  end-page: 94
  ident: bb0260
  article-title: Tumour evolution inferred by single-cell sequencing
  publication-title: Nature
– volume: 5
  start-page: 221
  year: 2005
  end-page: 230
  ident: bb0130
  article-title: Quantitative real-time PCR for cancer detection - the lymphoma case
  publication-title: Expert. Rev. Mol. Diagn.
– volume: 24
  start-page: S18
  year: 1997
  end-page: S30
  ident: bb0575
  article-title: Folate and antifolate phamracology
  publication-title: Semin. Oncol.
– volume: 7
  start-page: 185
  year: 2012
  end-page: 197
  ident: bb0770
  article-title: Two-in-one: combined targeted chemo and gene therapy for tumor suppression and prevention of metastases
  publication-title: Nanomedicine (Lond.)
– volume: 27
  start-page: 2296
  year: 2010
  end-page: 2306
  ident: bb0790
  article-title: Multifunctional tumor-targeted polymer-peptide-drug delivery system for treatment of primary and metastatic cancers
  publication-title: Pharm. Res.
– volume: 7
  start-page: 35
  year: 2007
  end-page: 45
  ident: bb0070
  article-title: Cancer phenomics: RET and PTEN as illustrative models
  publication-title: Nat. Rev. Cancer
– volume: 26
  start-page: 3785
  year: 2008
  end-page: 3790
  ident: bb0525
  article-title: A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair
  publication-title: J. Clin. Oncol.
– year: 2012
  ident: bb0060
  article-title: Computational Systems Biology of Cancer
– volume: 106
  start-page: 4402
  year: 2009
  end-page: 4407
  ident: bb0335
  article-title: Circulating microRNAs, potential biomarkers for drug-induced liver injury
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
– volume: 24
  start-page: 4317
  year: 2006
  end-page: 4323
  ident: bb0715
  article-title: ErbB-3 predicts survival in ovarian cancer
  publication-title: J. Clin. Oncol.
– reference: SOLO-2, Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy.
– volume: 65
  start-page: 1880
  year: 2013
  end-page: 1895
  ident: bb0765
  article-title: Nanotechnology approaches for personalized treatment of multidrug resistant cancers
  publication-title: Adv. Drug Deliv. Rev.
– volume: 113
  start-page: 205
  year: 2009
  end-page: 209
  ident: bb0735
  article-title: A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer
  publication-title: Gynecol. Oncol.
– volume: 11
  start-page: 1
  year: 2011
  end-page: 9
  ident: bb0475
  article-title: The PACOVAR-trial- a phase I:II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer
  publication-title: BMC Cancer
– volume: 1587
  start-page: 326
  year: 2002
  end-page: 337
  ident: bb0755
  article-title: Exemestane, a new steroidal aromatase inhibitor of clinical relevance
  publication-title: Biochim. Biophys. Acta (BBA) - Mol. Basis Dis.
– start-page: 5505
  year: 2013
  ident: bb0540
  article-title: Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm)
  publication-title: ASCO Annual Meeting
– volume: 65
  start-page: 5
  year: 2015
  end-page: 29
  ident: bb0010
  article-title: Cancer statistics, 2015
  publication-title: CA Cancer J. Clin.
– volume: 77
  start-page: 128
  year: 2014
  end-page: 136
  ident: bb0420
  article-title: New perspectives in ovarian cancer treatment
  publication-title: Maturitas
– volume: 4
  start-page: 668
  year: 2007
  end-page: 678
  ident: bb0800
  article-title: Targeted proapoptotic anticancer drug delivery system
  publication-title: Mol. Pharm.
– year: 2013
  ident: bb0500
  article-title: Randomised Double-Blind Phase III Trial of Cediranib (AZD 2171) in Relapsed Platinum Sensitive Ovarian Cancer: Results of the ICON6 Trial
– volume: 7
  start-page: 517
  year: 2006
  end-page: 528
  ident: bb0510
  article-title: Poly(ADP-ribose): novel functions for an old molecule
  publication-title: Nat. Rev. Mol. Cell Biol.
– volume: 20
  start-page: 889
  year: 2003
  end-page: 896
  ident: bb0815
  article-title: Targeted proapoptotic LHRH-BH3 peptide
  publication-title: Pharm. Res.
– volume: 39
  start-page: 1416
  year: 2007
  end-page: 1431
  ident: bb0215
  article-title: Rational bases for the development of EGFR inhibitors for cancer treatment
  publication-title: Int. J. Biochem. Cell Biol.
– volume: 161
  start-page: 1187
  year: 2015
  end-page: 1201
  ident: bb0315
  article-title: Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells
  publication-title: Cell
– volume: 31
  start-page: 3487
  year: 2014
  end-page: 3502
  ident: bb0205
  article-title: Tumor-targeted responsive nanoparticle-based systems for magnetic resonance imaging and therapy
  publication-title: Pharm. Res.
– volume: 12
  start-page: 1321
  year: 2011
  end-page: 1336
  ident: bb0590
  article-title: Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity
  publication-title: Pharmacogenomics
– volume: 62
  start-page: 270
  year: 2009
  end-page: 275
  ident: bb0030
  article-title: Diverse molecular pathways in ovarian cancer and their clinical significance
  publication-title: Maturitas
– volume: 498
  start-page: 236
  year: 2013
  end-page: 240
  ident: bb0295
  article-title: Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells
  publication-title: Nature
– reference: LUME-Ovar-1, LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer.
– volume: 13
  start-page: 45
  year: 2015
  ident: bb0035
  article-title: New horizons in tumor microenvironment biology: challenges and opportunities
  publication-title: BMC Med.
– year: 2015
  ident: bb0145
  article-title: Epigenome-based personalized medicine in human cancer
  publication-title: Epigenomics
– volume: 298
  start-page: 580
  year: 2002
  end-page: 584
  ident: bb0255
  article-title: Microfluidic large-scale integration
  publication-title: Science
– volume: 148
  start-page: 886
  year: 2012
  end-page: 895
  ident: bb0275
  article-title: Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor
  publication-title: Cell
– volume: 91
  start-page: 596
  year: 2003
  end-page: 602
  ident: bb0745
  article-title: Phase II trial of anastrozole in women with asymptomatic mullerian cancer
  publication-title: Gynecol. Oncol.
– year: 2012
  ident: bb0450
  article-title: AURELIA: a randomized phase III trail evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum(PT)-resistant ovarian cancer (OC)
  publication-title: ASCO Meetings Abstracts 30
– reference: Endocyte, Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED).
– volume: 455
  start-page: 1061
  year: 2008
  end-page: 1068
  ident: bb0840
  article-title: Comprehensive genomic characterization defines human glioblastoma genes and core pathways
  publication-title: Nature
– year: 2016
  ident: bb0200
  article-title: Nanoparticle design considerations for molecular imaging of apoptosis: diagnostic, prognostic, and therapeutic value
  publication-title: Adv. Drug Deliv. Rev.
– year: 2012
  ident: bb0445
  article-title: Updated overall survival analysis in OCEANS, a randomized phase 3 trail of gemcitabine
  publication-title: ESMO Annual Meeting
– volume: 128
  start-page: 356
  year: 2013
  end-page: 363
  ident: bb0180
  article-title: Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression
  publication-title: Gynecol. Oncol.
– volume: 2
  start-page: 666
  year: 2012
  end-page: 673
  ident: bb0305
  article-title: CEL-seq: single-cell RNA-seq by multiplexed linear amplification
  publication-title: Cell Rep.
– volume: 110
  start-page: 534
  year: 2007
  end-page: 542
  ident: bb0340
  article-title: Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence
  publication-title: Cancer
– volume: 25
  start-page: 1010
  year: 2011
  end-page: 1022
  ident: bb0160
  article-title: CpG islands and the regulation of transcription
  publication-title: Genes Dev.
– volume: 166
  start-page: 755
  year: 2016
  end-page: 765
  ident: bb0185
  article-title: C. Investigators, integrated proteogenomic characterization of human high-grade serous ovarian cancer
  publication-title: Cell
– volume: 111
  start-page: 13948
  year: 2014
  end-page: 13953
  ident: bb0195
  article-title: Deep, noninvasive imaging and surgical guidance of submillimeter tumors using targeted M13-stabilized single-walled carbon nanotubes
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
– volume: 359
  start-page: 1243
  year: 2008
  end-page: 1253
  ident: bb0090
  article-title: Inherited susceptibility to common cancers
  publication-title: N. Engl. J. Med.
– volume: 14
  start-page: 15885
  year: 2013
  end-page: 15909
  ident: bb0395
  article-title: Angiogenesis-related pathways in the pathogenesis of ovarian cancer
  publication-title: Int. J. Mol. Sci.
– volume: 19
  start-page: 6193
  year: 2013
  end-page: 6204
  ident: bb0775
  article-title: Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug
  publication-title: Clin. Cancer Res.
– volume: 74
  start-page: 193
  year: 1997
  end-page: 198
  ident: bb0610
  article-title: Overexpression of folate binding protein in ovarian cancers
  publication-title: Int. J. Cancer
– volume: 2015
  year: 2015
  ident: bb0080
  article-title: Cancer Facts and Figures
– volume: 21
  start-page: 379
  year: 2000
  end-page: 385
  ident: bb0020
  article-title: Significance of multiple mutations in cancer
  publication-title: Carcinogeneis
– volume: 199
  start-page: 215
  year: 2008
  end-page: 223
  ident: bb0370
  article-title: The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?
  publication-title: Am. J. Obstet. Gynecol.
– volume: 235
  start-page: 177
  year: 1987
  end-page: 182
  ident: bb0670
  article-title: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
  publication-title: Science
– year: 2009
  ident: bb0055
  article-title: Systems Biomedicine: Concepts and Perspectives
– volume: 100
  start-page: 3983
  year: 2003
  end-page: 3988
  ident: bb0225
  article-title: Prospective identification of tumorigenic breast cancer cells
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
– volume: 76
  start-page: 1221
  year: 1997
  end-page: 1227
  ident: bb0415
  article-title: Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms- correlation with clinicopathology and patient survival, and analysis of erum VEGF levels
  publication-title: Br. J. Cancer
– volume: 3
  start-page: 296
  year: 2013
  ident: bb0075
  article-title: Current status and evolution of preclinical drug development models of epithelial ovarian cancer
  publication-title: Front. Oncol.
– volume: 315
  start-page: 971
  year: 2005
  end-page: 979
  ident: bb0465
  article-title: Role of tyrosine kinase inhibitors in cancer therapy
  publication-title: J. Pharmacol. Exp. Ther.
– volume: 13
  start-page: 3617
  year: 2007
  end-page: 3622
  ident: bb0750
  article-title: Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients
  publication-title: Clin. Cancer Res.
– volume: 76
  start-page: 2004
  year: 1995
  end-page: 2010
  ident: bb0360
  article-title: Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers
  publication-title: Cancer
– volume: 31
  start-page: 4959
  year: 2003
  end-page: 4964
  ident: bb0520
  article-title: Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination
  publication-title: Nucleic Acids Res.
– volume: Vol. 20
  start-page: 1390
  year: 1963
  end-page: 1427
  ident: bb0655
  article-title: The Vinca Alkaloids - a New Class of Oncolytic Agents
– volume: 16
  start-page: 5093
  year: 2006
  end-page: 5096
  ident: bb0650
  article-title: Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide
  publication-title: Bioorg. Med. Chem. Lett.
– volume: 434
  start-page: 913
  year: 2005
  end-page: 917
  ident: bb0515
  article-title: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
  publication-title: Nature
– volume: 2012
  start-page: 245756
  year: 2012
  ident: bb0410
  article-title: Prognostic significance of vascular endothelial growth factor serum determination in women with ovarian cancer
  publication-title: ISRN Obstet. Gynecol.
– reference: C. Oncology, A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2).
– volume: 28
  start-page: 1215
  year: 2010
  end-page: 1223
  ident: bb0700
  article-title: Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
  publication-title: J. Clin. Oncol.
– volume: 45
  start-page: 1415
  year: 2009
  end-page: 1423
  ident: bb0600
  article-title: A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer
  publication-title: Eur. J. Cancer
– volume: 111
  start-page: 2297
  year: 2014
  end-page: 2307
  ident: bb0620
  article-title: Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An ovarian tumour tissue analysis consortium study
  publication-title: Br. J. Cancer
– volume: 99
  start-page: 267
  year: 2005
  end-page: 277
  ident: bb0355
  article-title: Potential markers that complement expression of CA125 in epithelial ovarian cancer
  publication-title: Gynecol. Oncol.
– volume: 78
  start-page: 530
  year: 2013
  end-page: 537
  ident: bb0730
  article-title: New insights on the role of hormonal therapy in ovarian cancer
  publication-title: Steroids
– volume: 161
  start-page: 1202
  year: 2015
  end-page: 1214
  ident: bb0310
  article-title: Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets
  publication-title: Cell
– volume: 65
  start-page: 1665
  year: 2013
  end-page: 1666
  ident: bb0780
  article-title: Nanotechnology and drug resistance
  publication-title: Adv. Drug Deliv. Rev.
– volume: 35
  start-page: 9
  year: 2012
  end-page: 18
  ident: bb0615
  article-title: The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer
  publication-title: Cell Oncol. (Dordr.)
– reference: M. Pharmaceuticals, A Study of MM-121 With Paclitaxel in Platinum Resistant/Refractory Advanced Ovarian Cancers. Vol. 12.19.15.
– volume: 19
  start-page: A68
  year: 2015
  end-page: A77
  ident: bb0835
  article-title: The cancer genome atlas (TCGA): an immeasurable source of knowledge
  publication-title: Contemp. Oncol. (Pozn)
– volume: 3
  start-page: 761
  year: 2008
  end-page: 776
  ident: bb0795
  article-title: Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer
  publication-title: Nanomedicine (Lond.)
– volume: 3
  start-page: 27
  year: 2004
  ident: bb0140
  article-title: Gene expression profiling of epithelial ovarian tumours correlated with malignant potential
  publication-title: Mol. Cancer
– volume: 271
  start-page: 111
  year: 2012
  end-page: 121
  ident: bb0040
  article-title: Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine
  publication-title: J. Intern. Med.
– volume: 56
  start-page: 1127
  year: 2004
  end-page: 1141
  ident: bb0645
  article-title: Folate-targeted chemotherapy
  publication-title: Adv. Drug Deliv. Rev.
– volume: 624
  start-page: 281
  year: 2010
  end-page: 294
  ident: bb0785
  article-title: LHRH-targeted nanoparticles for cancer therapeutics
  publication-title: Methods Mol. Biol.
– volume: 5
  start-page: 317
  year: 2004
  end-page: 328
  ident: bb0710
  article-title: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
  publication-title: Cancer Cell
– volume: 13
  start-page: 255
  year: 2016
  end-page: 261
  ident: bb0380
  article-title: Can advanced-stage ovarian cancer be cured?
  publication-title: Nat. Rev. Clin. Oncol.
– volume: 129
  start-page: 452
  year: 2013
  end-page: 458
  ident: bb0635
  article-title: Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer
  publication-title: Gynecol. Oncol.
– volume: 22
  start-page: 417
  year: 2015
  end-page: 430
  ident: bb0115
  article-title: A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance
  publication-title: Cancer Gene Ther.
– reference: J. Lopez, S. Banerjee, S.B. Kaye, New developments in the treatment of ovarian cancer–future perspectives, Ann. Oncol., 24 Suppl 10 (2013) x69-x76.
– volume: 20
  start-page: 436
  year: 2014
  end-page: 442
  ident: bb0325
  article-title: Multiplexed ion beam imaging of human breast tumors
  publication-title: Nat. Med.
– volume: 126
  start-page: 1885
  year: 2016
  end-page: 1896
  ident: bb0385
  article-title: FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal
  publication-title: J. Clin. Invest.
– volume: 285
  start-page: 1182
  year: 1971
  end-page: 1186
  ident: bb0390
  article-title: Tumor angiogenesis: therapeutic implications
  publication-title: N. Engl. J. Med.
– volume: 35
  start-page: 125
  year: 2012
  end-page: 128
  ident: bb0365
  article-title: Tumour markers
  publication-title: Aust. Prescr.
– volume: 68
  start-page: 4774
  year: 2008
  end-page: 4782
  ident: bb0470
  article-title: BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy
  publication-title: Cancer Res.
– volume: 6
  start-page: 360
  year: 2012
  end-page: 369
  ident: bb0625
  article-title: Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response
  publication-title: Mol. Oncol.
– volume: 29
  start-page: 1120
  year: 2012
  end-page: 1127
  ident: bb0285
  article-title: Single-cell dissection of transcriptional heterogeneity in human colon tumors
  publication-title: Nat. Biotechnol.
– volume: 34
  start-page: 433
  year: 2010
  end-page: 443
  ident: bb0025
  article-title: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory
  publication-title: Am. J. Surg. Pathol.
– volume: 31
  start-page: 576
  year: 2015
  end-page: 586
  ident: bb0300
  article-title: Single-cell analysis in cancer genomics
  publication-title: Trends Genet.
– volume: 333
  start-page: 328
  year: 2005
  end-page: 335
  ident: bb0425
  article-title: Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
  publication-title: Biochem. Biophys. Res. Commun.
– volume: 3
  start-page: 330
  year: 2003
  end-page: 338
  ident: bb0585
  article-title: 5-Fluorouracil: mechanisms of action and clinical strategies
  publication-title: Nat. Rev. Cancer
– volume: Vol. 2015
  year: 2014
  ident: bb0015
  article-title: Ovarian Cancer
– volume: 10
  start-page: 1108
  year: 2013
  end-page: 1115
  ident: bb0245
  article-title: Network-based stratification of tumor mutations
  publication-title: Nat. Methods
– reference: ICON6, An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer (ICON6).
– volume: 9
  start-page: 1
  year: 2015
  end-page: 5
  ident: bb0220
  article-title: Use of targeted liposome-based chemotherapeutics to treat breast cancer
  publication-title: Breast Cancer (Auckl.)
– volume: 34
  start-page: 3215
  year: 2015
  end-page: 3225
  ident: bb0045
  article-title: Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies
  publication-title: Oncogene
– reference: Morphotek, Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse.
– volume: 67
  start-page: 1030
  year: 2007
  end-page: 1037
  ident: bb0230
  article-title: Identification of pancreatic cancer stem cells
  publication-title: Cancer Res.
– volume: 10
  start-page: 1501
  year: 2014
  end-page: 1513
  ident: bb0350
  article-title: Current status of circulating protein biomarkers to aid the early detection of lung cancer
  publication-title: Future Oncol.
– volume: 69
  start-page: 4
  year: 2005
  end-page: 10
  ident: bb0405
  article-title: VEGF as a key mediator of angiogenesis in cancer
  publication-title: Oncology
– volume: 99
  start-page: 5261
  year: 2002
  end-page: 5266
  ident: bb0265
  article-title: Comprehensive human genome amplification using multiple displacement amplification
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
– volume: 138
  start-page: 795
  year: 2009
  end-page: 806
  ident: bb0210
  article-title: Full dynamic range proteome analysis of
  publication-title: Cell
– volume: 60
  start-page: 496
  year: 1997
  end-page: 504
  ident: bb0105
  article-title: Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer - results from three US population-based case-control studies of ovarian cancer
  publication-title: Am. Soc. Hum. Genet.
– volume: Vol. 7
  start-page: 125
  year: 2015
  end-page: 132
  ident: bb0685
  article-title: The Expanding Role of Pertuzumab in the Treatment of HER2-Positive Breast Cancer
– volume: 12
  start-page: 337
  year: 2003
  end-page: 351
  ident: bb0740
  article-title: The therapeutic potential of aromatase inhibitors
  publication-title: Expert Opin. Investig. Drugs
– volume: 102
  start-page: 12962
  year: 2005
  end-page: 12967
  ident: bb0825
  article-title: Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
– start-page: 59
  year: 2015
  end-page: 80
  ident: bb0175
  publication-title: Advances in Cancer Biomarkers
– volume: 127
  start-page: 2893
  year: 2010
  end-page: 2917
  ident: bb0005
  article-title: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
  publication-title: Int. J. Cancer
– volume: 12
  start-page: 39
  year: 2001
  end-page: 46
  ident: bb0135
  article-title: A real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect breast carcinoma cells in peripheral blood
  publication-title: Ann. Oncol.
– volume: 365
  start-page: 2484
  year: 2011
  end-page: 2496
  ident: bb0435
  article-title: A phase 3 trial of bevacizumab in ovarian cancer
  publication-title: N. Engl. J. Med.
– volume: 30
  start-page: 2654
  year: 2012
  end-page: 2663
  ident: bb0085
  article-title: BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group
  publication-title: J. Clin. Oncol.
– volume: 131
  start-page: 535
  year: 2013
  end-page: 540
  ident: bb0605
  article-title: Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer
  publication-title: Gynecol. Oncol.
– volume: 501
  year: 2013
  ident: bb0240
  article-title: Tumour heterogeneity in the clinic
  publication-title: Nature
– volume: 31
  start-page: 4400
  year: 2013
  end-page: 4406
  ident: bb0660
  article-title: PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer
  publication-title: J. Clin. Oncol.
– volume: 16
  start-page: 109
  year: 2007
  end-page: 117
  ident: bb0250
  article-title: A method for single-cell sorting and expansion of genetically modified human embryonic stem cells
  publication-title: Stem Cells Dev.
– volume: 18
  start-page: 5911
  year: 2012
  end-page: 5923
  ident: bb0725
  article-title: Src inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo
  publication-title: Clin. Cancer Res.
– volume: 148
  start-page: 873
  year: 2012
  end-page: 885
  ident: bb0270
  article-title: Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm
  publication-title: Cell
– volume: 4
  start-page: 322
  year: 2014
  ident: bb0190
  article-title: Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer
  publication-title: Front. Oncol.
– volume: 113
  start-page: 341
  year: 2009
  end-page: 347
  ident: bb0675
  article-title: Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a gynecologic oncology group study
  publication-title: Gynecol. Oncol.
– reference: H.-L. Roche, A Study of Pertuzumab in Combination With Standard Chemotherapy in Women With Recurrent Platinum-Resistant Epithelian Ovarian Cancer and Low HER3 mRNA Expression.
– volume: 118
  start-page: 429
  year: 2011
  end-page: 432
  ident: bb0505
  article-title: PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine
  publication-title: BJOG
– volume: 769
  start-page: 93
  year: 2015
  end-page: 99
  ident: bb0595
  article-title: Functional variants of gene encoding folate metabolizing enzyme and methotrexate-related toxicity in children with acute lymphoblastic leukemia
  publication-title: Eur. J. Pharmacol.
– volume: 19
  start-page: 305
  year: 2011
  end-page: 316
  ident: bb0065
  article-title: Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain
  publication-title: Cancer Cell
– volume: 30
  start-page: 777
  year: 2012
  end-page: 782
  ident: bb0290
  article-title: Full-length mRNA-seq from single-cell levels of RNA and individual circulating tumor cells
  publication-title: Nat. Biotechnol.
– volume: 18
  start-page: 1
  year: 2014
  end-page: 80
  ident: bb0680
  article-title: Trastuzumab-containing regimens for metastatic breast cancer
  publication-title: Cochrane Database Syst. Rev.
– volume: 366
  start-page: 1382
  year: 2012
  end-page: 1392
  ident: bb0545
  article-title: Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
  publication-title: N. Engl. J. Med.
– volume: 133
  year: 2013
  ident: bb0095
  article-title: Next-generation sequencing: methodology and application
  publication-title: J. Invest. Dermatol.
– volume: 12
  start-page: 7
  year: 2011
  end-page: 18
  ident: bb0170
  article-title: Charting histone modifications and the functional organization of mammalian genomes
  publication-title: Nat. Rev. Genet.
– volume: 6
  start-page: 377
  year: 2009
  end-page: 382
  ident: bb0280
  article-title: mRNA-seq whole transcriptome analysis of a single cell
  publication-title: Nat. Methods
– reference: AURELIA, AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer. Vol. 12.05.15.
– volume: 91
  start-page: 61
  year: 2003
  end-page: 73
  ident: bb0820
  article-title: Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides
  publication-title: J. Control. Release
– volume: 26
  start-page: 2034
  year: 2015
  end-page: 2043
  ident: bb0630
  article-title: Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments
  publication-title: Ann. Oncol.
– volume: 24
  year: 2006
  ident: bb0760
  article-title: Phase II study of exemestane (E) in refractory ovarian cancer (ROC)
  publication-title: J. Clin. Oncol.
– reference: SOLO-1, Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1).
– reference: D.R. Rhodes, A.M. Chinnaiyan, Integrative analysis of the cancer transcriptome, Nat. Genet., 37 (Suppl. 2005) S31–37.
– volume: 66
  start-page: 1272
  year: 2000
  end-page: 2000
  ident: bb0100
  article-title: BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer
  publication-title: Am. Soc. Hum. Genet.
– volume: 68
  start-page: 700
  year: 2001
  end-page: 710
  ident: bb0110
  article-title: Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population of 649 women with ovarian cancer
  publication-title: Am. Soc. Hum. Genet.
– volume: 316
  start-page: 992
  year: 2006
  end-page: 998
  ident: bb0810
  article-title: Molecular targeting of BCL2 and BCLXL proteins by synthetic BCL2 homology 3 domain peptide enhances the efficacy of chemotherapy
  publication-title: J. Pharmacol. Exp. Ther.
– volume: 305
  start-page: 2295
  year: 2011
  end-page: 2303
  ident: bb0330
  article-title: Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial
  publication-title: JAMA
– volume: 30
  start-page: 2039
  year: 2012
  end-page: 2045
  ident: bb0440
  article-title: OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
  publication-title: J. Clin. Oncol.
– volume: 332
  start-page: 687
  year: 2011
  end-page: 696
  ident: bb0320
  article-title: Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum
  publication-title: Science
– reference: Tesaro, A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer.
– volume: 63
  start-page: 5821
  year: 2003
  end-page: 5828
  ident: bb0235
  article-title: Identification of a cancer stem cell in human brain tumors
  publication-title: Cancer Res.
– volume: Vol. 31
  year: 2013
  ident: bb0480
  article-title: A Phase III, Randomized, Double-Blind Trial of Pazopanib Versus Placebo in Women Who Have Not Progressed After First-Line Chemotherapy for Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (AEOC): Results of an International Intergroup Trial (AGO-OVAR 16)
– volume: 99
  start-page: 13481
  year: 2002
  end-page: 13486
  ident: bb0580
  article-title: Interaction of dihydrofolate reductase with methotrexate: ensemble and single-molecule kinetics
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
– reference: GSK, Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women.
– volume: 327
  start-page: 996
  year: 2010
  end-page: 1000
  ident: bb0165
  article-title: Regulation of alternative splicing by histone modifications
  publication-title: Science
– volume: 365
  start-page: 2473
  year: 2011
  end-page: 2483
  ident: bb0430
  article-title: Incorporation of bevacizumab in the primary treatment of ovarian cancer
  publication-title: N. Engl. J. Med.
– volume: 271
  start-page: 603
  year: 1996
  end-page: 606
  ident: bb0400
  article-title: Vascular endothelial growth factor, a potent and selective angiogenic agent
  publication-title: J. Biol. Chem.
– volume: 140
  start-page: 284
  year: 2009
  end-page: 293
  ident: bb0830
  article-title: Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery
  publication-title: J. Control. Release
– volume: 24
  start-page: 4317
  year: 2006
  ident: 10.1016/j.jconrel.2016.10.014_bb0715
  article-title: ErbB-3 predicts survival in ovarian cancer
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2005.04.8397
– volume: 113
  start-page: 205
  year: 2009
  ident: 10.1016/j.jconrel.2016.10.014_bb0735
  article-title: A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer
  publication-title: Gynecol. Oncol.
  doi: 10.1016/j.ygyno.2009.01.012
– volume: 271
  start-page: 111
  year: 2012
  ident: 10.1016/j.jconrel.2016.10.014_bb0040
  article-title: Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine
  publication-title: J. Intern. Med.
  doi: 10.1111/j.1365-2796.2011.02498.x
– volume: 327
  start-page: 996
  year: 2010
  ident: 10.1016/j.jconrel.2016.10.014_bb0165
  article-title: Regulation of alternative splicing by histone modifications
  publication-title: Science
  doi: 10.1126/science.1184208
– volume: 18
  start-page: 1
  year: 2014
  ident: 10.1016/j.jconrel.2016.10.014_bb0680
  article-title: Trastuzumab-containing regimens for metastatic breast cancer
  publication-title: Cochrane Database Syst. Rev.
– volume: 68
  start-page: 700
  year: 2001
  ident: 10.1016/j.jconrel.2016.10.014_bb0110
  article-title: Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population of 649 women with ovarian cancer
  publication-title: Am. Soc. Hum. Genet.
  doi: 10.1086/318787
– ident: 10.1016/j.jconrel.2016.10.014_bb0495
– volume: 67
  start-page: 1030
  year: 2007
  ident: 10.1016/j.jconrel.2016.10.014_bb0230
  article-title: Identification of pancreatic cancer stem cells
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-06-2030
– volume: Vol. 20
  start-page: 1390
  year: 1963
  ident: 10.1016/j.jconrel.2016.10.014_bb0655
– volume: 30
  start-page: 2039
  year: 2012
  ident: 10.1016/j.jconrel.2016.10.014_bb0440
  article-title: OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2012.42.0505
– ident: 10.1016/j.jconrel.2016.10.014_bb0375
  doi: 10.1093/annonc/mdt475
– volume: 2015
  year: 2015
  ident: 10.1016/j.jconrel.2016.10.014_bb0080
– volume: 148
  start-page: 873
  year: 2012
  ident: 10.1016/j.jconrel.2016.10.014_bb0270
  article-title: Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm
  publication-title: Cell
  doi: 10.1016/j.cell.2012.02.028
– volume: 25
  start-page: 1010
  year: 2011
  ident: 10.1016/j.jconrel.2016.10.014_bb0160
  article-title: CpG islands and the regulation of transcription
  publication-title: Genes Dev.
  doi: 10.1101/gad.2037511
– volume: 65
  start-page: 1665
  year: 2013
  ident: 10.1016/j.jconrel.2016.10.014_bb0780
  article-title: Nanotechnology and drug resistance
  publication-title: Adv. Drug Deliv. Rev.
  doi: 10.1016/j.addr.2013.10.005
– volume: 285
  start-page: 1182
  year: 1971
  ident: 10.1016/j.jconrel.2016.10.014_bb0390
  article-title: Tumor angiogenesis: therapeutic implications
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJM197111182852108
– volume: 21
  start-page: 379
  year: 2000
  ident: 10.1016/j.jconrel.2016.10.014_bb0020
  article-title: Significance of multiple mutations in cancer
  publication-title: Carcinogeneis
  doi: 10.1093/carcin/21.3.379
– volume: Vol. 7
  start-page: 125
  year: 2015
  ident: 10.1016/j.jconrel.2016.10.014_bb0685
– volume: 106
  start-page: 4402
  year: 2009
  ident: 10.1016/j.jconrel.2016.10.014_bb0335
  article-title: Circulating microRNAs, potential biomarkers for drug-induced liver injury
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.0813371106
– volume: 99
  start-page: 13481
  year: 2002
  ident: 10.1016/j.jconrel.2016.10.014_bb0580
  article-title: Interaction of dihydrofolate reductase with methotrexate: ensemble and single-molecule kinetics
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.172501499
– start-page: 59
  year: 2015
  ident: 10.1016/j.jconrel.2016.10.014_bb0175
– volume: 16
  start-page: 5093
  year: 2006
  ident: 10.1016/j.jconrel.2016.10.014_bb0650
  article-title: Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2006.07.030
– volume: 18
  start-page: 5911
  year: 2012
  ident: 10.1016/j.jconrel.2016.10.014_bb0725
  article-title: Src inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-12-1257
– volume: 12
  start-page: 7
  year: 2011
  ident: 10.1016/j.jconrel.2016.10.014_bb0170
  article-title: Charting histone modifications and the functional organization of mammalian genomes
  publication-title: Nat. Rev. Genet.
  doi: 10.1038/nrg2905
– volume: 26
  start-page: 3785
  year: 2008
  ident: 10.1016/j.jconrel.2016.10.014_bb0525
  article-title: A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2008.16.0812
– volume: 235
  start-page: 177
  year: 1987
  ident: 10.1016/j.jconrel.2016.10.014_bb0670
  article-title: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
  publication-title: Science
  doi: 10.1126/science.3798106
– volume: 31
  start-page: 3487
  year: 2014
  ident: 10.1016/j.jconrel.2016.10.014_bb0205
  article-title: Tumor-targeted responsive nanoparticle-based systems for magnetic resonance imaging and therapy
  publication-title: Pharm. Res.
  doi: 10.1007/s11095-014-1436-x
– volume: 24
  year: 2006
  ident: 10.1016/j.jconrel.2016.10.014_bb0760
  article-title: Phase II study of exemestane (E) in refractory ovarian cancer (ROC)
  publication-title: J. Clin. Oncol.
  doi: 10.1200/jco.2006.24.18_suppl.5026
– volume: 131
  start-page: 535
  year: 2013
  ident: 10.1016/j.jconrel.2016.10.014_bb0605
  article-title: Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer
  publication-title: Gynecol. Oncol.
  doi: 10.1016/j.ygyno.2013.09.032
– volume: 140
  start-page: 284
  year: 2009
  ident: 10.1016/j.jconrel.2016.10.014_bb0830
  article-title: Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2009.06.019
– volume: 166
  start-page: 755
  year: 2016
  ident: 10.1016/j.jconrel.2016.10.014_bb0185
  article-title: C. Investigators, integrated proteogenomic characterization of human high-grade serous ovarian cancer
  publication-title: Cell
  doi: 10.1016/j.cell.2016.05.069
– volume: 111
  start-page: 13948
  year: 2014
  ident: 10.1016/j.jconrel.2016.10.014_bb0195
  article-title: Deep, noninvasive imaging and surgical guidance of submillimeter tumors using targeted M13-stabilized single-walled carbon nanotubes
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.1400821111
– volume: 9
  start-page: 1
  year: 2015
  ident: 10.1016/j.jconrel.2016.10.014_bb0220
  article-title: Use of targeted liposome-based chemotherapeutics to treat breast cancer
  publication-title: Breast Cancer (Auckl.)
– volume: 91
  start-page: 596
  year: 2003
  ident: 10.1016/j.jconrel.2016.10.014_bb0745
  article-title: Phase II trial of anastrozole in women with asymptomatic mullerian cancer
  publication-title: Gynecol. Oncol.
  doi: 10.1016/j.ygyno.2003.08.021
– volume: 45
  start-page: 1415
  year: 2009
  ident: 10.1016/j.jconrel.2016.10.014_bb0600
  article-title: A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2008.12.013
– volume: 13
  start-page: 3617
  year: 2007
  ident: 10.1016/j.jconrel.2016.10.014_bb0750
  article-title: Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-06-2878
– volume: 298
  start-page: 580
  year: 2002
  ident: 10.1016/j.jconrel.2016.10.014_bb0255
  article-title: Microfluidic large-scale integration
  publication-title: Science
  doi: 10.1126/science.1076996
– volume: 129
  start-page: 452
  year: 2013
  ident: 10.1016/j.jconrel.2016.10.014_bb0635
  article-title: Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer
  publication-title: Gynecol. Oncol.
  doi: 10.1016/j.ygyno.2013.03.002
– volume: 31
  start-page: 576
  year: 2015
  ident: 10.1016/j.jconrel.2016.10.014_bb0300
  article-title: Single-cell analysis in cancer genomics
  publication-title: Trends Genet.
  doi: 10.1016/j.tig.2015.07.003
– volume: 769
  start-page: 93
  year: 2015
  ident: 10.1016/j.jconrel.2016.10.014_bb0595
  article-title: Functional variants of gene encoding folate metabolizing enzyme and methotrexate-related toxicity in children with acute lymphoblastic leukemia
  publication-title: Eur. J. Pharmacol.
  doi: 10.1016/j.ejphar.2015.10.058
– volume: 2012
  start-page: 245756
  year: 2012
  ident: 10.1016/j.jconrel.2016.10.014_bb0410
  article-title: Prognostic significance of vascular endothelial growth factor serum determination in women with ovarian cancer
  publication-title: ISRN Obstet. Gynecol.
  doi: 10.5402/2012/245756
– volume: 11
  start-page: 1
  year: 2011
  ident: 10.1016/j.jconrel.2016.10.014_bb0475
  article-title: The PACOVAR-trial- a phase I:II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-11-453
– volume: 26
  start-page: 2034
  year: 2015
  ident: 10.1016/j.jconrel.2016.10.014_bb0630
  article-title: Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdv250
– volume: 126
  start-page: 1885
  year: 2016
  ident: 10.1016/j.jconrel.2016.10.014_bb0385
  article-title: FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI85086
– volume: 7
  start-page: 185
  year: 2012
  ident: 10.1016/j.jconrel.2016.10.014_bb0770
  article-title: Two-in-one: combined targeted chemo and gene therapy for tumor suppression and prevention of metastases
  publication-title: Nanomedicine (Lond.)
  doi: 10.2217/nnm.11.131
– year: 2010
  ident: 10.1016/j.jconrel.2016.10.014_bb0050
– ident: 10.1016/j.jconrel.2016.10.014_bb0570
– volume: 110
  start-page: 534
  year: 2007
  ident: 10.1016/j.jconrel.2016.10.014_bb0340
  article-title: Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence
  publication-title: Cancer
  doi: 10.1002/cncr.22774
– volume: 6
  start-page: 1197
  year: 2013
  ident: 10.1016/j.jconrel.2016.10.014_bb0535
  article-title: Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib
  publication-title: Onco. Targets Ther.
– volume: 29
  start-page: 1547
  year: 2011
  ident: 10.1016/j.jconrel.2016.10.014_bb0345
  article-title: Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2010.30.5151
– volume: 359
  start-page: 1243
  year: 2008
  ident: 10.1016/j.jconrel.2016.10.014_bb0090
  article-title: Inherited susceptibility to common cancers
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMra0802968
– volume: 5
  start-page: 221
  year: 2005
  ident: 10.1016/j.jconrel.2016.10.014_bb0130
  article-title: Quantitative real-time PCR for cancer detection - the lymphoma case
  publication-title: Expert. Rev. Mol. Diagn.
  doi: 10.1586/14737159.5.2.221
– year: 2013
  ident: 10.1016/j.jconrel.2016.10.014_bb0500
– volume: 12
  start-page: 337
  year: 2003
  ident: 10.1016/j.jconrel.2016.10.014_bb0740
  article-title: The therapeutic potential of aromatase inhibitors
  publication-title: Expert Opin. Investig. Drugs
  doi: 10.1517/13543784.12.3.337
– volume: 69
  start-page: 4
  year: 2005
  ident: 10.1016/j.jconrel.2016.10.014_bb0405
  article-title: VEGF as a key mediator of angiogenesis in cancer
  publication-title: Oncology
  doi: 10.1159/000088478
– volume: 13
  start-page: 45
  year: 2015
  ident: 10.1016/j.jconrel.2016.10.014_bb0035
  article-title: New horizons in tumor microenvironment biology: challenges and opportunities
  publication-title: BMC Med.
  doi: 10.1186/s12916-015-0278-7
– volume: 20
  start-page: 889
  year: 2003
  ident: 10.1016/j.jconrel.2016.10.014_bb0815
  article-title: Targeted proapoptotic LHRH-BH3 peptide
  publication-title: Pharm. Res.
  doi: 10.1023/A:1023839319950
– volume: 99
  start-page: 267
  year: 2005
  ident: 10.1016/j.jconrel.2016.10.014_bb0355
  article-title: Potential markers that complement expression of CA125 in epithelial ovarian cancer
  publication-title: Gynecol. Oncol.
  doi: 10.1016/j.ygyno.2005.06.040
– volume: 14
  start-page: 15885
  year: 2013
  ident: 10.1016/j.jconrel.2016.10.014_bb0395
  article-title: Angiogenesis-related pathways in the pathogenesis of ovarian cancer
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms140815885
– volume: 78
  start-page: 530
  year: 2013
  ident: 10.1016/j.jconrel.2016.10.014_bb0730
  article-title: New insights on the role of hormonal therapy in ovarian cancer
  publication-title: Steroids
  doi: 10.1016/j.steroids.2013.01.008
– volume: 63
  start-page: 5821
  year: 2003
  ident: 10.1016/j.jconrel.2016.10.014_bb0235
  article-title: Identification of a cancer stem cell in human brain tumors
  publication-title: Cancer Res.
– ident: 10.1016/j.jconrel.2016.10.014_bb0560
– volume: 27
  start-page: 2296
  year: 2010
  ident: 10.1016/j.jconrel.2016.10.014_bb0790
  article-title: Multifunctional tumor-targeted polymer-peptide-drug delivery system for treatment of primary and metastatic cancers
  publication-title: Pharm. Res.
  doi: 10.1007/s11095-010-0235-2
– ident: 10.1016/j.jconrel.2016.10.014_bb0455
– volume: 29
  start-page: 1120
  year: 2012
  ident: 10.1016/j.jconrel.2016.10.014_bb0285
  article-title: Single-cell dissection of transcriptional heterogeneity in human colon tumors
  publication-title: Nat. Biotechnol.
  doi: 10.1038/nbt.2038
– year: 2012
  ident: 10.1016/j.jconrel.2016.10.014_bb0450
  article-title: AURELIA: a randomized phase III trail evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum(PT)-resistant ovarian cancer (OC)
– volume: Vol. 10
  start-page: 470
  year: 2009
  ident: 10.1016/j.jconrel.2016.10.014_bb0460
– volume: 77
  start-page: 128
  year: 2014
  ident: 10.1016/j.jconrel.2016.10.014_bb0420
  article-title: New perspectives in ovarian cancer treatment
  publication-title: Maturitas
  doi: 10.1016/j.maturitas.2013.11.009
– year: 2015
  ident: 10.1016/j.jconrel.2016.10.014_bb0145
  article-title: Epigenome-based personalized medicine in human cancer
  publication-title: Epigenomics
– volume: 19
  start-page: 6193
  year: 2013
  ident: 10.1016/j.jconrel.2016.10.014_bb0775
  article-title: Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-13-1536
– volume: 3
  start-page: 296
  year: 2013
  ident: 10.1016/j.jconrel.2016.10.014_bb0075
  article-title: Current status and evolution of preclinical drug development models of epithelial ovarian cancer
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2013.00296
– volume: 365
  start-page: 2473
  year: 2011
  ident: 10.1016/j.jconrel.2016.10.014_bb0430
  article-title: Incorporation of bevacizumab in the primary treatment of ovarian cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1104390
– volume: 22
  start-page: 417
  year: 2015
  ident: 10.1016/j.jconrel.2016.10.014_bb0115
  article-title: A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance
  publication-title: Cancer Gene Ther.
  doi: 10.1038/cgt.2015.39
– volume: 315
  start-page: 971
  year: 2005
  ident: 10.1016/j.jconrel.2016.10.014_bb0465
  article-title: Role of tyrosine kinase inhibitors in cancer therapy
  publication-title: J. Pharmacol. Exp. Ther.
  doi: 10.1124/jpet.105.084145
– volume: 74
  start-page: 193
  year: 1997
  ident: 10.1016/j.jconrel.2016.10.014_bb0610
  article-title: Overexpression of folate binding protein in ovarian cancers
  publication-title: Int. J. Cancer
  doi: 10.1002/(SICI)1097-0215(19970422)74:2<193::AID-IJC10>3.0.CO;2-F
– volume: 56
  start-page: 1127
  year: 2004
  ident: 10.1016/j.jconrel.2016.10.014_bb0645
  article-title: Folate-targeted chemotherapy
  publication-title: Adv. Drug Deliv. Rev.
  doi: 10.1016/j.addr.2004.01.008
– volume: 12
  start-page: 39
  year: 2001
  ident: 10.1016/j.jconrel.2016.10.014_bb0135
  article-title: A real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect breast carcinoma cells in peripheral blood
  publication-title: Ann. Oncol.
  doi: 10.1023/A:1008317512253
– volume: 60
  start-page: 496
  year: 1997
  ident: 10.1016/j.jconrel.2016.10.014_bb0105
  article-title: Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer - results from three US population-based case-control studies of ovarian cancer
  publication-title: Am. Soc. Hum. Genet.
– volume: 76
  start-page: 2004
  year: 1995
  ident: 10.1016/j.jconrel.2016.10.014_bb0360
  article-title: Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers
  publication-title: Cancer
  doi: 10.1002/1097-0142(19951115)76:10+<2004::AID-CNCR2820761317>3.0.CO;2-G
– volume: 51
  start-page: 6581
  year: 2008
  ident: 10.1016/j.jconrel.2016.10.014_bb0530
  article-title: 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one - a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1
  publication-title: J. Med. Chem.
  doi: 10.1021/jm8001263
– volume: 91
  start-page: 61
  year: 2003
  ident: 10.1016/j.jconrel.2016.10.014_bb0820
  article-title: Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides
  publication-title: J. Control. Release
  doi: 10.1016/S0168-3659(03)00209-8
– volume: 501
  year: 2013
  ident: 10.1016/j.jconrel.2016.10.014_bb0240
  article-title: Tumour heterogeneity in the clinic
  publication-title: Nature
  doi: 10.1038/nature12627
– volume: 30
  start-page: 2654
  year: 2012
  ident: 10.1016/j.jconrel.2016.10.014_bb0085
  article-title: BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2011.39.8545
– volume: 16
  start-page: 109
  year: 2007
  ident: 10.1016/j.jconrel.2016.10.014_bb0250
  article-title: A method for single-cell sorting and expansion of genetically modified human embryonic stem cells
  publication-title: Stem Cells Dev.
  doi: 10.1089/scd.2006.0059
– volume: 1587
  start-page: 326
  year: 2002
  ident: 10.1016/j.jconrel.2016.10.014_bb0755
  article-title: Exemestane, a new steroidal aromatase inhibitor of clinical relevance
  publication-title: Biochim. Biophys. Acta (BBA) - Mol. Basis Dis.
  doi: 10.1016/S0925-4439(02)00096-0
– ident: 10.1016/j.jconrel.2016.10.014_bb0485
– volume: 118
  start-page: 429
  year: 2011
  ident: 10.1016/j.jconrel.2016.10.014_bb0505
  article-title: PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine
  publication-title: BJOG
  doi: 10.1111/j.1471-0528.2010.02838.x
– ident: 10.1016/j.jconrel.2016.10.014_bb0565
– volume: 347
  start-page: 1999
  year: 2002
  ident: 10.1016/j.jconrel.2016.10.014_bb0150
  article-title: A Gene-expression signature as a predictor of survival in breast cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa021967
– volume: 161
  start-page: 1187
  year: 2015
  ident: 10.1016/j.jconrel.2016.10.014_bb0315
  article-title: Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells
  publication-title: Cell
  doi: 10.1016/j.cell.2015.04.044
– volume: 332
  start-page: 687
  year: 2011
  ident: 10.1016/j.jconrel.2016.10.014_bb0320
  article-title: Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum
  publication-title: Science
  doi: 10.1126/science.1198704
– volume: 199
  start-page: 215
  year: 2008
  ident: 10.1016/j.jconrel.2016.10.014_bb0370
  article-title: The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?
  publication-title: Am. J. Obstet. Gynecol.
  doi: 10.1016/j.ajog.2008.04.009
– year: 2016
  ident: 10.1016/j.jconrel.2016.10.014_bb0200
  article-title: Nanoparticle design considerations for molecular imaging of apoptosis: diagnostic, prognostic, and therapeutic value
  publication-title: Adv. Drug Deliv. Rev.
  doi: 10.1016/j.addr.2016.06.016
– volume: 100
  start-page: 3983
  year: 2003
  ident: 10.1016/j.jconrel.2016.10.014_bb0225
  article-title: Prospective identification of tumorigenic breast cancer cells
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.0530291100
– volume: 2
  start-page: 666
  year: 2012
  ident: 10.1016/j.jconrel.2016.10.014_bb0305
  article-title: CEL-seq: single-cell RNA-seq by multiplexed linear amplification
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2012.08.003
– volume: Vol. 2015
  year: 2014
  ident: 10.1016/j.jconrel.2016.10.014_bb0015
– volume: 7
  start-page: 517
  year: 2006
  ident: 10.1016/j.jconrel.2016.10.014_bb0510
  article-title: Poly(ADP-ribose): novel functions for an old molecule
  publication-title: Nat. Rev. Mol. Cell Biol.
  doi: 10.1038/nrm1963
– volume: 34
  start-page: 433
  year: 2010
  ident: 10.1016/j.jconrel.2016.10.014_bb0025
  article-title: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory
  publication-title: Am. J. Surg. Pathol.
  doi: 10.1097/PAS.0b013e3181cf3d79
– volume: 161
  start-page: 1202
  year: 2015
  ident: 10.1016/j.jconrel.2016.10.014_bb0310
  article-title: Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets
  publication-title: Cell
  doi: 10.1016/j.cell.2015.05.002
– ident: 10.1016/j.jconrel.2016.10.014_bb0665
– volume: 24
  start-page: S18
  year: 1997
  ident: 10.1016/j.jconrel.2016.10.014_bb0575
  article-title: Folate and antifolate phamracology
  publication-title: Semin. Oncol.
– volume: 128
  start-page: 356
  year: 2013
  ident: 10.1016/j.jconrel.2016.10.014_bb0180
  article-title: Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression
  publication-title: Gynecol. Oncol.
  doi: 10.1016/j.ygyno.2012.11.036
– volume: 20
  start-page: 436
  year: 2014
  ident: 10.1016/j.jconrel.2016.10.014_bb0325
  article-title: Multiplexed ion beam imaging of human breast tumors
  publication-title: Nat. Med.
  doi: 10.1038/nm.3488
– volume: 76
  start-page: 1221
  year: 1997
  ident: 10.1016/j.jconrel.2016.10.014_bb0415
  article-title: Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms- correlation with clinicopathology and patient survival, and analysis of erum VEGF levels
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.1997.537
– volume: 133
  year: 2013
  ident: 10.1016/j.jconrel.2016.10.014_bb0095
  article-title: Next-generation sequencing: methodology and application
  publication-title: J. Invest. Dermatol.
  doi: 10.1038/jid.2013.248
– volume: 2
  year: 2010
  ident: 10.1016/j.jconrel.2016.10.014_bb0120
  article-title: Development of personalized tumor biomarkers using massively parallel sequencing
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.3000702
– volume: 6
  start-page: 377
  year: 2009
  ident: 10.1016/j.jconrel.2016.10.014_bb0280
  article-title: mRNA-seq whole transcriptome analysis of a single cell
  publication-title: Nat. Methods
  doi: 10.1038/nmeth.1315
– year: 2012
  ident: 10.1016/j.jconrel.2016.10.014_bb0445
– volume: 4
  start-page: 668
  year: 2007
  ident: 10.1016/j.jconrel.2016.10.014_bb0800
  article-title: Targeted proapoptotic anticancer drug delivery system
  publication-title: Mol. Pharm.
  doi: 10.1021/mp070053o
– volume: 498
  start-page: 236
  year: 2013
  ident: 10.1016/j.jconrel.2016.10.014_bb0295
  article-title: Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells
  publication-title: Nature
  doi: 10.1038/nature12172
– volume: 10
  start-page: 1108
  year: 2013
  ident: 10.1016/j.jconrel.2016.10.014_bb0245
  article-title: Network-based stratification of tumor mutations
  publication-title: Nat. Methods
  doi: 10.1038/nmeth.2651
– volume: 39
  start-page: 1416
  year: 2007
  ident: 10.1016/j.jconrel.2016.10.014_bb0215
  article-title: Rational bases for the development of EGFR inhibitors for cancer treatment
  publication-title: Int. J. Biochem. Cell Biol.
  doi: 10.1016/j.biocel.2007.05.008
– volume: 31
  start-page: 4959
  year: 2003
  ident: 10.1016/j.jconrel.2016.10.014_bb0520
  article-title: Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gkg703
– volume: 624
  start-page: 281
  year: 2010
  ident: 10.1016/j.jconrel.2016.10.014_bb0785
  article-title: LHRH-targeted nanoparticles for cancer therapeutics
  publication-title: Methods Mol. Biol.
  doi: 10.1007/978-1-60761-609-2_19
– volume: 65
  start-page: 5
  year: 2015
  ident: 10.1016/j.jconrel.2016.10.014_bb0010
  article-title: Cancer statistics, 2015
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21254
– volume: 35
  start-page: 9
  year: 2012
  ident: 10.1016/j.jconrel.2016.10.014_bb0615
  article-title: The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer
  publication-title: Cell Oncol. (Dordr.)
  doi: 10.1007/s13402-011-0052-6
– volume: 62
  start-page: 270
  year: 2009
  ident: 10.1016/j.jconrel.2016.10.014_bb0030
  article-title: Diverse molecular pathways in ovarian cancer and their clinical significance
  publication-title: Maturitas
  doi: 10.1016/j.maturitas.2009.01.001
– volume: 3
  start-page: 27
  year: 2004
  ident: 10.1016/j.jconrel.2016.10.014_bb0140
  article-title: Gene expression profiling of epithelial ovarian tumours correlated with malignant potential
  publication-title: Mol. Cancer
  doi: 10.1186/1476-4598-3-27
– volume: 333
  start-page: 328
  year: 2005
  ident: 10.1016/j.jconrel.2016.10.014_bb0425
  article-title: Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2005.05.132
– year: 2012
  ident: 10.1016/j.jconrel.2016.10.014_bb0060
– volume: 305
  start-page: 2295
  year: 2011
  ident: 10.1016/j.jconrel.2016.10.014_bb0330
  article-title: Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial
  publication-title: JAMA
  doi: 10.1001/jama.2011.766
– volume: 138
  start-page: 795
  year: 2009
  ident: 10.1016/j.jconrel.2016.10.014_bb0210
  article-title: Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics
  publication-title: Cell
  doi: 10.1016/j.cell.2009.05.051
– volume: 6
  start-page: 537
  year: 2006
  ident: 10.1016/j.jconrel.2016.10.014_bb0805
  article-title: New generation of liposomal drugs for cancer
  publication-title: Anti Cancer Agents Med. Chem.
  doi: 10.2174/187152006778699095
– start-page: 5505
  year: 2013
  ident: 10.1016/j.jconrel.2016.10.014_bb0540
  article-title: Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm)
– ident: 10.1016/j.jconrel.2016.10.014_bb0550
– volume: 31
  start-page: 4400
  year: 2013
  ident: 10.1016/j.jconrel.2016.10.014_bb0660
  article-title: PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2013.49.7685
– volume: 19
  start-page: A68
  year: 2015
  ident: 10.1016/j.jconrel.2016.10.014_bb0835
  article-title: The cancer genome atlas (TCGA): an immeasurable source of knowledge
  publication-title: Contemp. Oncol. (Pozn)
– volume: 19
  start-page: 305
  year: 2011
  ident: 10.1016/j.jconrel.2016.10.014_bb0065
  article-title: Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2011.01.039
– ident: 10.1016/j.jconrel.2016.10.014_bb0720
– volume: 65
  start-page: 1880
  year: 2013
  ident: 10.1016/j.jconrel.2016.10.014_bb0765
  article-title: Nanotechnology approaches for personalized treatment of multidrug resistant cancers
  publication-title: Adv. Drug Deliv. Rev.
  doi: 10.1016/j.addr.2013.09.017
– volume: 13
  start-page: 255
  year: 2016
  ident: 10.1016/j.jconrel.2016.10.014_bb0380
  article-title: Can advanced-stage ovarian cancer be cured?
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/nrclinonc.2015.224
– volume: 99
  start-page: 5261
  year: 2002
  ident: 10.1016/j.jconrel.2016.10.014_bb0265
  article-title: Comprehensive human genome amplification using multiple displacement amplification
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.082089499
– volume: 12
  start-page: 1321
  year: 2011
  ident: 10.1016/j.jconrel.2016.10.014_bb0590
  article-title: Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs.11.72
– volume: 111
  start-page: 2297
  year: 2014
  ident: 10.1016/j.jconrel.2016.10.014_bb0620
  article-title: Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An ovarian tumour tissue analysis consortium study
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.2014.567
– volume: 4
  start-page: 322
  year: 2014
  ident: 10.1016/j.jconrel.2016.10.014_bb0190
  article-title: Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2014.00322
– volume: 68
  start-page: 4774
  year: 2008
  ident: 10.1016/j.jconrel.2016.10.014_bb0470
  article-title: BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-07-6307
– volume: 66
  start-page: 1272
  year: 2000
  ident: 10.1016/j.jconrel.2016.10.014_bb0100
  article-title: BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer
  publication-title: Am. Soc. Hum. Genet.
– volume: 24
  start-page: 4324
  year: 2006
  ident: 10.1016/j.jconrel.2016.10.014_bb0695
  article-title: Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2005.05.4221
– ident: 10.1016/j.jconrel.2016.10.014_bb0705
– volume: 113
  start-page: 341
  year: 2009
  ident: 10.1016/j.jconrel.2016.10.014_bb0675
  article-title: Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a gynecologic oncology group study
  publication-title: Gynecol. Oncol.
  doi: 10.1016/j.ygyno.2009.02.009
– volume: 434
  start-page: 913
  year: 2005
  ident: 10.1016/j.jconrel.2016.10.014_bb0515
  article-title: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
  publication-title: Nature
  doi: 10.1038/nature03443
– volume: 3
  start-page: 761
  year: 2008
  ident: 10.1016/j.jconrel.2016.10.014_bb0795
  article-title: Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer
  publication-title: Nanomedicine (Lond.)
  doi: 10.2217/17435889.3.6.761
– volume: 455
  start-page: 1061
  year: 2008
  ident: 10.1016/j.jconrel.2016.10.014_bb0840
  article-title: Comprehensive genomic characterization defines human glioblastoma genes and core pathways
  publication-title: Nature
  doi: 10.1038/nature07385
– volume: 127
  start-page: 2893
  year: 2010
  ident: 10.1016/j.jconrel.2016.10.014_bb0005
  article-title: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.25516
– volume: 10
  start-page: 1501
  year: 2014
  ident: 10.1016/j.jconrel.2016.10.014_bb0350
  article-title: Current status of circulating protein biomarkers to aid the early detection of lung cancer
  publication-title: Future Oncol.
  doi: 10.2217/fon.14.21
– volume: 34
  start-page: 3215
  year: 2015
  ident: 10.1016/j.jconrel.2016.10.014_bb0045
  article-title: Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies
  publication-title: Oncogene
  doi: 10.1038/onc.2014.291
– volume: 366
  start-page: 1382
  year: 2012
  ident: 10.1016/j.jconrel.2016.10.014_bb0545
  article-title: Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1105535
– ident: 10.1016/j.jconrel.2016.10.014_bb0640
– volume: Vol. 31
  year: 2013
  ident: 10.1016/j.jconrel.2016.10.014_bb0480
– volume: 35
  start-page: 125
  year: 2012
  ident: 10.1016/j.jconrel.2016.10.014_bb0365
  article-title: Tumour markers
  publication-title: Aust. Prescr.
  doi: 10.18773/austprescr.2012.052
– volume: 271
  start-page: 603
  year: 1996
  ident: 10.1016/j.jconrel.2016.10.014_bb0400
  article-title: Vascular endothelial growth factor, a potent and selective angiogenic agent
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.271.2.603
– volume: 30
  start-page: 777
  year: 2012
  ident: 10.1016/j.jconrel.2016.10.014_bb0290
  article-title: Full-length mRNA-seq from single-cell levels of RNA and individual circulating tumor cells
  publication-title: Nat. Biotechnol.
  doi: 10.1038/nbt.2282
– volume: 472
  start-page: 90
  year: 2011
  ident: 10.1016/j.jconrel.2016.10.014_bb0260
  article-title: Tumour evolution inferred by single-cell sequencing
  publication-title: Nature
  doi: 10.1038/nature09807
– volume: 28
  start-page: 1215
  year: 2010
  ident: 10.1016/j.jconrel.2016.10.014_bb0700
  article-title: Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2009.22.3354
– ident: 10.1016/j.jconrel.2016.10.014_bb0490
– year: 2009
  ident: 10.1016/j.jconrel.2016.10.014_bb0055
– volume: 3
  start-page: 330
  year: 2003
  ident: 10.1016/j.jconrel.2016.10.014_bb0585
  article-title: 5-Fluorouracil: mechanisms of action and clinical strategies
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc1074
– volume: 21
  start-page: 283
  year: 2003
  ident: 10.1016/j.jconrel.2016.10.014_bb0690
  article-title: Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the gynecologic oncology group
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2003.10.104
– volume: 365
  start-page: 2484
  year: 2011
  ident: 10.1016/j.jconrel.2016.10.014_bb0435
  article-title: A phase 3 trial of bevacizumab in ovarian cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1103799
– volume: 7
  start-page: 35
  year: 2007
  ident: 10.1016/j.jconrel.2016.10.014_bb0070
  article-title: Cancer phenomics: RET and PTEN as illustrative models
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc2037
– volume: 6
  start-page: 360
  year: 2012
  ident: 10.1016/j.jconrel.2016.10.014_bb0625
  article-title: Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response
  publication-title: Mol. Oncol.
  doi: 10.1016/j.molonc.2011.11.010
– volume: 5
  start-page: 317
  year: 2004
  ident: 10.1016/j.jconrel.2016.10.014_bb0710
  article-title: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
  publication-title: Cancer Cell
  doi: 10.1016/S1535-6108(04)00083-2
– volume: 102
  start-page: 12962
  year: 2005
  ident: 10.1016/j.jconrel.2016.10.014_bb0825
  article-title: Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.0504274102
– ident: 10.1016/j.jconrel.2016.10.014_bb0125
  doi: 10.1038/ng1570
– volume: 148
  start-page: 886
  year: 2012
  ident: 10.1016/j.jconrel.2016.10.014_bb0275
  article-title: Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor
  publication-title: Cell
  doi: 10.1016/j.cell.2012.02.025
– volume: 339
  start-page: 1546
  year: 2013
  ident: 10.1016/j.jconrel.2016.10.014_bb0155
  article-title: Cancer genome landscapes
  publication-title: Science
  doi: 10.1126/science.1235122
– ident: 10.1016/j.jconrel.2016.10.014_bb0555
– volume: 316
  start-page: 992
  year: 2006
  ident: 10.1016/j.jconrel.2016.10.014_bb0810
  article-title: Molecular targeting of BCL2 and BCLXL proteins by synthetic BCL2 homology 3 domain peptide enhances the efficacy of chemotherapy
  publication-title: J. Pharmacol. Exp. Ther.
  doi: 10.1124/jpet.105.094243
– reference: 24377084 - Front Oncol. 2013 Dec 11;3:296
– reference: 12605559 - Expert Opin Investig Drugs. 2003 Mar;12(3):337-51
– reference: 11179017 - Am J Hum Genet. 2001 Mar;68(3):700-10
– reference: 24037242 - Nat Methods. 2013 Nov;10(11):1108-15
– reference: 23539594 - Science. 2013 Mar 29;339(6127):1546-58
– reference: 18772890 - Nature. 2008 Oct 23;455(7216):1061-8
– reference: 12930944 - Nucleic Acids Res. 2003 Sep 1;31(17):4959-64
– reference: 19567257 - J Control Release. 2009 Dec 16;140(3):284-93
– reference: 27374457 - Adv Drug Deliv Rev. 2016 Jun 29;:null
– reference: 16002463 - J Pharmacol Exp Ther. 2005 Dec;315(3):971-9
– reference: 17100558 - Anticancer Agents Med Chem. 2006 Nov;6(6):537-52
– reference: 24380827 - Maturitas. 2014 Feb;77(2):128-36
– reference: 22204724 - N Engl J Med. 2011 Dec 29;365(26):2473-83
– reference: 16061277 - Gynecol Oncol. 2005 Nov;99(2):267-77
– reference: 12525520 - J Clin Oncol. 2003 Jan 15;21(2):283-90
– reference: 26309409 - Breast Cancer (Auckl). 2015 Aug 10;9(Suppl 2):1-5
– reference: 4938153 - N Engl J Med. 1971 Nov 18;285(21):1182-6
– reference: 22385957 - Cell. 2012 Mar 2;148(5):873-85
– reference: 25478323 - Front Oncol. 2014 Nov 18;4:322
– reference: 12084475 - Biochim Biophys Acta. 2002 Jul 18;1587(2-3):326-37
– reference: 22142401 - J Intern Med. 2012 Feb;271(2):111-21
– reference: 26787282 - Nat Rev Clin Oncol. 2016 Apr;13(4):255-61
– reference: 23219462 - Gynecol Oncol. 2013 Feb;128(2):356-63
– reference: 24096113 - Gynecol Oncol. 2013 Dec;131(3):535-40
– reference: 20700631 - Pharm Res. 2010 Nov;27(11):2296-306
– reference: 20371490 - Sci Transl Med. 2010 Feb 24;2(20):20ra14
– reference: 26450340 - Trends Genet. 2015 Oct;31(10):576-86
– reference: 19901115 - J Clin Oncol. 2010 Mar 1;28(7):1215-23
– reference: 16870437 - Bioorg Med Chem Lett. 2006 Oct 1;16(19):5093-6
– reference: 24177352 - Adv Drug Deliv Rev. 2013 Nov;65(13-14):1665-6
– reference: 12629218 - Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8
– reference: 20133523 - Science. 2010 Feb 19;327(5968):996-1000
– reference: 12817893 - Pharm Res. 2003 Jun;20(6):889-96
– reference: 15093539 - Cancer Cell. 2004 Apr;5(4):317-28
– reference: 22452356 - N Engl J Med. 2012 Apr 12;366(15):1382-92
– reference: 9133455 - Int J Cancer. 1997 Apr 22;74(2):193-8
– reference: 22014006 - BMC Cancer. 2011 Oct 20;11:453
– reference: 19349980 - Nat Methods. 2009 May;6(5):377-82
– reference: 24048068 - Nature. 2013 Sep 19;501(7467):355-64
– reference: 18559524 - Cancer Res. 2008 Jun 15;68(12):4774-82
– reference: 21397855 - Cancer Cell. 2011 Mar 8;19(3):305-16
– reference: 20154587 - Am J Surg Pathol. 2010 Mar;34(3):433-43
– reference: 21351269 - Int J Cancer. 2010 Dec 15;127(12):2893-917
– reference: 26528799 - Eur J Pharmacol. 2015 Dec 15;769:93-9
– reference: 12724731 - Nat Rev Cancer. 2003 May;3(5):330-8
– reference: 26344672 - Epigenomics. 2016 Jan;8(1):119-33
– reference: 19168349 - Eur J Cancer. 2009 May;45(8):1415-23
– reference: 16291730 - J Pharmacol Exp Ther. 2006 Mar;316(3):992-8
– reference: 17283135 - Cancer Res. 2007 Feb 1;67(3):1030-7
– reference: 26056489 - Breast Cancer (Dove Med Press). 2015 May 21;7:125-32
– reference: 27064283 - J Clin Invest. 2016 May 2;126(5):1885-96
– reference: 15961063 - Biochem Biophys Res Commun. 2005 Jul 29;333(2):328-35
– reference: 22265591 - Mol Oncol. 2012 Jun;6(3):360-9
– reference: 17685579 - Mol Pharm. 2007 Sep-Oct;4(5):668-78
– reference: 3798106 - Science. 1987 Jan 9;235(4785):177-82
– reference: 14675683 - Gynecol Oncol. 2003 Dec;91(3):596-602
– reference: 19239974 - Gynecol Oncol. 2009 May;113(2):205-9
– reference: 26000488 - Cell. 2015 May 21;161(5):1202-14
– reference: 17596994 - Int J Biochem Cell Biol. 2007;39(7-8):1416-31
– reference: 15920528 - Nat Genet. 2005 Jun;37 Suppl:S31-7
– reference: 26063635 - Ann Oncol. 2015 Oct;26(10):2034-43
– reference: 21244617 - BJOG. 2011 Mar;118(4):429-32
– reference: 10739756 - Am J Hum Genet. 2000 Apr;66(4):1259-72
– reference: 16123131 - Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12962-7
– reference: 18468571 - Am J Obstet Gynecol. 2008 Sep;199(3):215-23
– reference: 18591545 - J Clin Oncol. 2008 Aug 1;26(22):3785-90
– reference: 8557658 - J Biol Chem. 1996 Jan 12;271(2):603-6
– reference: 24127448 - J Clin Oncol. 2013 Dec 10;31(35):4400-6
– reference: 20217603 - Methods Mol Biol. 2010;624:281-94
– reference: 24919460 - Cochrane Database Syst Rev. 2014 Jun 12;(6):CD006242
– reference: 15829966 - Nature. 2005 Apr 14;434(7035):913-7
– reference: 27372738 - Cell. 2016 Jul 28;166(3):755-65
– reference: 9365173 - Br J Cancer. 1997;76(9):1221-7
– reference: 23402742 - Steroids. 2013 Jun;78(6):530-7
– reference: 25220419 - Oncogene. 2015 Jun;34(25):3215-25
– reference: 24584119 - Nat Med. 2014 Apr;20(4):436-42
– reference: 24120655 - Adv Drug Deliv Rev. 2013 Nov;65(13-14):1880-95
– reference: 23685454 - Nature. 2013 Jun 13;498(7453):236-40
– reference: 24043945 - Onco Targets Ther. 2013 Sep 03;6:1197-206
– reference: 14522905 - Cancer Res. 2003 Sep 15;63(18):5821-8
– reference: 16896006 - J Clin Oncol. 2006 Sep 10;24(26):4324-32
– reference: 15471544 - Mol Cancer. 2004 Oct 07;3:27
– reference: 9042908 - Am J Hum Genet. 1997 Mar;60(3):496-504
– reference: 23474348 - Gynecol Oncol. 2013 Jun;129(3):452-8
– reference: 21422427 - J Clin Oncol. 2011 Apr 20;29(12 ):1547-55
– reference: 17167516 - Nat Rev Cancer. 2007 Jan;7(1):35-45
– reference: 22339132 - Nanomedicine (Lond). 2012 Feb;7(2):185-97
– reference: 24265409 - Ann Oncol. 2013 Dec;24 Suppl 10:x69-x76
– reference: 12359872 - Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13481-6
– reference: 21919607 - Pharmacogenomics. 2011 Sep;12(9):1321-36
– reference: 21551058 - Science. 2011 May 6;332(6030):687-96
– reference: 8634992 - Cancer. 1995 Nov 15;76(10 Suppl):2004-10
– reference: 19005198 - N Engl J Med. 2008 Nov 13;359(20):2143-53
– reference: 26000487 - Cell. 2015 May 21;161(5):1187-201
– reference: 22385958 - Cell. 2012 Mar 2;148(5):886-95
– reference: 24036854 - Clin Cancer Res. 2013 Nov 15;19(22):6193-204
– reference: 12932638 - J Control Release. 2003 Aug 28;91(1-2):61-73
– reference: 19025451 - Nanomedicine (Lond). 2008 Dec;3(6):761-76
– reference: 10688858 - Carcinogenesis. 2000 Mar;21(3):379-85
– reference: 25214538 - Proc Natl Acad Sci U S A. 2014 Sep 23;111(38):13948-53
– reference: 23856935 - J Invest Dermatol. 2013 Aug;133(8):e11
– reference: 11249047 - Ann Oncol. 2001 Jan;12(1):39-46
– reference: 11959976 - Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5261-6
– reference: 22711857 - J Clin Oncol. 2012 Jul 20;30(21):2654-63
– reference: 22896656 - Clin Cancer Res. 2012 Nov 1;18(21):5911-23
– reference: 25349970 - Br J Cancer. 2014 Dec 9;111(12):2297-307
– reference: 26358176 - Cancer Gene Ther. 2015 Sep;22(9):417-30
– reference: 21576262 - Genes Dev. 2011 May 15;25(10):1010-22
– reference: 9420019 - Semin Oncol. 1997 Oct;24(5 Suppl 18):S18-30-S18-39
– reference: 17594720 - Cancer. 2007 Aug 1;110(3):534-42
– reference: 17348809 - Stem Cells Dev. 2007 Feb;16(1):109-17
– reference: 19689244 - Curr Drug Metab. 2009 Jun;10(5):470-81
– reference: 16829982 - Nat Rev Mol Cell Biol. 2006 Jul;7(7):517-28
– reference: 21399628 - Nature. 2011 Apr 7;472(7341):90-4
– reference: 16301830 - Oncology. 2005;69 Suppl 3:4-10
– reference: 25857315 - BMC Med. 2015 Mar 05;13:45
– reference: 25052758 - Future Oncol. 2014 Jun;10(8):1501-13
– reference: 25559415 - CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
– reference: 18800822 - J Med Chem. 2008 Oct 23;51(20):6581-91
– reference: 19246379 - Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4402-7
– reference: 23903048 - Int J Mol Sci. 2013 Jul 30;14(8):15885-909
– reference: 22792477 - ISRN Obstet Gynecol. 2012;2012:245756
– reference: 15094211 - Adv Drug Deliv Rev. 2004 Apr 29;56(8):1127-41
– reference: 21647742 - Cell Oncol (Dordr). 2012 Feb;35(1):9-18
– reference: 22081019 - Nat Biotechnol. 2011 Nov 13;29(12):1120-7
– reference: 25691825 - Contemp Oncol (Pozn). 2015;19(1A):A68-77
– reference: 21116306 - Nat Rev Genet. 2011 Jan;12(1):7-18
– reference: 19193504 - Maturitas. 2009 Mar 20;62(3):270-5
– reference: 22204725 - N Engl J Med. 2011 Dec 29;365(26):2484-96
– reference: 24919932 - Pharm Res. 2014 Dec;31(12 ):3487-502
– reference: 12490681 - N Engl J Med. 2002 Dec 19;347(25):1999-2009
– reference: 15833051 - Expert Rev Mol Diagn. 2005 Mar;5(2):221-30
– reference: 19272639 - Gynecol Oncol. 2009 Jun;113(3):341-7
– reference: 22820318 - Nat Biotechnol. 2012 Aug;30(8):777-82
– reference: 22939981 - Cell Rep. 2012 Sep 27;2(3):666-73
– reference: 22529265 - J Clin Oncol. 2012 Jun 10;30(17):2039-45
– reference: 16896008 - J Clin Oncol. 2006 Sep 10;24(26):4317-23
– reference: 19664813 - Cell. 2009 Aug 21;138(4):795-806
– reference: 12351675 - Science. 2002 Oct 18;298(5593):580-4
– reference: 17575226 - Clin Cancer Res. 2007 Jun 15;13(12):3617-22
– reference: 21642681 - JAMA. 2011 Jun 8;305(22):2295-303
– reference: 14070392 - Cancer Res. 1963 Sep;23:1390-427
SSID ssj0005347
Score 2.4588857
SecondaryResourceType review_article
Snippet The review is aimed at describing modern approaches to detection as well as precision and personalized treatment of ovarian cancer. Modern methods and future...
SourceID pubmedcentral
proquest
pubmed
crossref
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 250
SubjectTerms animal ovaries
Animals
Female
Genetic profiling
Humans
Molecular Targeted Therapy
Nanotechnology
Nanotechnology - methods
ovarian neoplasms
Ovarian Neoplasms - diagnosis
Ovarian Neoplasms - therapy
Personalized medicine
Precision Medicine - methods
siRNA
Targeted therapy
therapeutics
Title Precision targeted therapy of ovarian cancer
URI https://dx.doi.org/10.1016/j.jconrel.2016.10.014
https://www.ncbi.nlm.nih.gov/pubmed/27746277
https://www.proquest.com/docview/1835437366
https://www.proquest.com/docview/2000238388
https://pubmed.ncbi.nlm.nih.gov/PMC5191987
Volume 243
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8NAEB60XryIb-ujrCCemrbJPrI9SlGqohRU8Bby2MUWSaVWoRd_uzPNprWKCF5CstkNm9nHfLM78y3AyZQO0GruBWTpCGuVl4jA9wxHY0HKWIWCAoVvblX3QVw9yscl6JSxMORW6eb-Yk6fztYupemk2Xzp95t3CFY0VxLxDUcc3pbLsBKgttcVWDm7vO7ezj09uCiippX2qMA8kKc5aAzQ7BwZ2oTwVYP8vHzxm4r6CUG_e1J-UU0X67DmMCU7K6q9AUsm34TTXkFKPamz-3mM1WudnbLenK56sgX13sids8MKt3CTsSIqa8KGlg3f0ZqOc5ZS9xhtw8PF-X2n67kzFLxUhq2xJ1LayjMiFDohppzUYMvYAA3fhMukTXGzcYC3RhIyStEYaiVoMatEtmOVqZjvQCUf5mYPGGJFRDtoYhgbiMRmcWpDjp_x29JmPs-qIEqxRakjGKdzLp6j0pNsEDlpRyRtSkZpV6ExK_ZSMGz8VUCXbRItdJUItcBfRY_LNoxwGNHeSJyb4dtr5NMCGA-5Ur_nCabsQJprXYXdot1nNQ4QRiu8VCFc6BGzDETjvfgm7z9N6bwRQ9PKz_7_f-sAVumJvGz81iFUxqM3c4RYaZzUYLnx4dfciPgEmKAS9w
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1JSytBEC40Hp4XcXnvGdcWxFMmyUwvMzmKKHELASN4a2bpxgSZSIxC_r1VmZ7EKCJ4GYZehp6qXr7qrvoa4HhKB2gj7gVk6QhrlZeIwPcMR2NByliFggKFbzuqfS-uHuTDEpyVsTDkVunm_mJOn87WLqXhpNl47vcbdwhWIq4k4huOOLwll2FF0KXWFVg5vbxud-aeHlwUUdMq8qjCPJCnMagP0OwcGTqE8FWd_Lx88d0S9RWCfvak_LA0XazDmsOU7LRo9gYsmXwTTroFKfWkxnrzGKuXGjth3Tld9WQLat2Ru2eHFW7hJmNFVNaEDS0bvqE1Hecspe4x-gv3F-e9s7bn7lDwUhk2x55I6SjPiFBECTHlpAY1YwM0fBMukxbFzcYBvhpJyChFY6iZoMWsEtmKVaZi_g8q-TA328AQKyLaQRPD2EAkNotTG3L8jN-SNvN5VgVRik2njmCc7rl40qUn2UA7aWuSNiWjtKtQn1V7Lhg2fqoQlTrRC11F4yrwU9WjUocahxGdjcS5Gb6-aJ82wHjIlfq-TDBlB4p4FFXhf6H3WYsDhNEKH1UIF3rErADReC_m5P3HKZ03Ymja-dn5_W8dwp927_ZG31x2rndhlXLI48Zv7kFlPHo1-4ibxsmBGxfvEK0U3Q
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Precision+targeted+therapy+of+ovarian+cancer&rft.jtitle=Journal+of+controlled+release&rft.au=Sapiezynski%2C+Justin&rft.au=Taratula%2C+Oleh&rft.au=Rodriguez-Rodriguez%2C+Lorna&rft.au=Minko%2C+Tamara&rft.date=2016-12-10&rft.pub=Elsevier+B.V&rft.issn=0168-3659&rft.eissn=1873-4995&rft.volume=243&rft.spage=250&rft.epage=268&rft_id=info:doi/10.1016%2Fj.jconrel.2016.10.014&rft.externalDocID=S0168365916309695
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0168-3659&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0168-3659&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0168-3659&client=summon